UROLOGY LANDMARK TRIALS

Natural History and Epidemiology Studies

The Olmsted County Study

🧬 Landmark Medical Therapy Trials

VA Cooperative Study #359

PLESS (Proscar Long-term Efficacy and Safety Study)

MTOPS (Medical Therapy of Prostatic Symptoms)

CombAT (Combination of Avodart and Tamsulosin)

The EPICS Trial: Dutasteride vs. Finasteride

🧑‍🤝‍🧑 Patient Population and Methods

The study enrolled 1,630 men aged 50 years or older with a clinical diagnosis of symptomatic BPH . They were randomized to receive one of two treatments once daily for 48 weeks :

• Dutasteride 0.5 mg (n = 813)

• Finasteride 5 mg (n = 817)

The primary endpoint was the change in prostate volume. Secondary endpoints included improvement in American Urological Association Symptom Index (AUA-SI) scores and maximum urinary flow rate (Qmax) .

📈 Key Results

The trial’s findings demonstrated that both drugs were similarly effective across all measured outcomes .

Silodosin vs Tamsulosin vs Alfuzosin

The table below summarizes the key findings from head-to-head trials and meta-analyses.

🧪 Solifenacin + Tamsulosin: The NEPTUNE Trial

The NEPTUNE trial (and its open-label extension NEPTUNE II) is the pivotal phase III study establishing the efficacy and safety of the fixed-dose combination of solifenacin and tamsulosin for men with both storage and voiding LUTS associated with BPH .

🧑‍🤝‍🧑 Patient Population and Methods

• Participants: 1,334 men with both storage and voiding LUTS associated with BPH .

• Inclusion Criteria: At least 2 urgency episodes/24h, ≥8 micturitions/24h, IPSS ≥13, Qmax 4.0–12.0 mL/s, voided volume ≥120 mL .

• Intervention: Patients were randomized to 12 weeks of:

  • Placebo

  • Tamsulosin (0.4 mg) monotherapy (oral controlled absorption system, OCAS)

  • Fixed-dose combination of solifenacin (6 mg or 9 mg) + tamsulosin 0.4 mg OCAS .

📊 Key Results

⚠️ Tolerability and Safety

• Most Common Adverse Events: Dry mouth, constipation, and dyspepsia (typical of anticholinergics) .

• Acute Urinary Retention (AUR): Occurred in <1% of patients .

• Long-Term Safety: The NEPTUNE II open-label extension confirmed the combination was generally well-tolerated over one year .

💡 Significance

NEPTUNE established that the fixed-dose combination of solifenacin and tamsulosin provides superior relief of storage symptoms compared to tamsulosin alone, with an acceptable safety profile, leading to regulatory approval of the combination tablet (Vesomni) .

⚡ Mirabegron + Tamsulosin: The Phase III Trial (2025)

This is the most recent landmark phase III trial evaluating the addition of mirabegron (a beta-3 agonist) to tamsulosin in men with LUTS due to BPH .

🧑‍🤝‍🧑 Patient Population and Methods

• Participants: 795 men with LUTS due to BPH .

• Intervention: 12 weeks of:

  • Tamsulosin monotherapy (0.2 mg? – details vary by region; 0.4 mg is standard in many countries) .

  • Mirabegron + Tamsulosin combination therapy .

• Primary Endpoints:

  1. Change in Total Urinary Frequency Score (TUFS) .

  2. Change in International Prostate Symptom Score (IPSS) .

📊 Key Results (12 Weeks)

⚠️ Safety Profile

The combination demonstrated a comparable safety profile to monotherapy, with no increase in adverse events, particularly no signal for increased urinary retention .

Summary of Key Tadalafil Trials in BPH

🔬 Minimally Invasive Surgical Therapy (MIST) Trials

CLEAR Trial (UroLift PUL vs. Rezūm WVTT)

Optilume BPH System (Drug-Coated Balloon)

💊 Emerging and Novel Therapies

COURAGE Trial (Vibegron for OAB in BPH Patients)

GV1001 vs. Finasteride Phase 3 Trial

LANDMARK PROSTATE CANCER TRIALS

🩺 SCREENING AND EARLY DETECTION

ERSPC (European Randomized Study of Screening for Prostate Cancer) – 23-Year Follow-up

Journal/Author: New England Journal of Medicine (Roobol MJ, et al., 2025)

Design: Multicenter, randomized trial conducted across 8 European countries.

Population: 162,236 men aged 55-69 years at randomization.

Primary Outcome: Prostate cancer mortality.

• Result: 13% reduction in the screening group (rate ratio, 0.87; 95% CI, 0.80-0.95).

Key Secondary Outcomes:

• Number needed to invite to screen (NNS) to prevent one death: 456 (95% CI, 306-943) at 23 years, improved from 628 at 16 years.

• Number needed to diagnose (NND) to prevent one death: 12 (95% CI, 8-26) at 23 years, improved from 18 at 16 years.

• Cumulative incidence of prostate cancer: Higher in screening group (rate ratio, 1.30).

Conclusion: PSA screening reduces prostate cancer mortality but at the cost of significant overdiagnosis. The benefits persist long-term but wane after screening stops, underscoring the need for risk-adapted approaches incorporating modern imaging.

Limitations: Significant overdiagnosis; only 24% of elevated PSA led to cancer on biopsy; mortality benefit wanes within 9 years of stopping screening; screening protocols varied across countries; does not reflect modern MRI-based strategies.

PLCO trial

The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial is a landmark study that has profoundly shaped the debate on prostate cancer screening. Its initial conclusion—that annual screening did not reduce prostate cancer mortality—has since been reevaluated due to significant flaws in the study’s design and execution.

📝 Study Design and Methods

The PLCO trial, sponsored by the National Cancer Institute (NCI), was a large, population-based, randomized controlled trial conducted at 10 centers across the U.S.. The prostate component, which began in 1993, enrolled 76,685 men aged 55-74 with no history of PLCO cancers.

Participants were randomized into two groups:

• Screening Group (n~38,350): Received annual PSA tests for 6 years and annual digital rectal exams (DRE) for 4 years.

• Control Group (n~38,350): Received standard medical care (i.e., no protocol-mandated screening).

📊 Key Findings and Interpretation

The study’s results led to its controversial legacy.

• No Mortality Benefit (Initial Finding): After 7 to 10 years of follow-up, there was no significant difference in prostate cancer-specific mortality between the screened and unscreened groups. This finding was instrumental in the 2012 U.S. Preventive Services Task Force (USPSTF) recommendation against PSA screening.

• Increased Diagnosis: The trial found that screening led to a significantly higher incidence of prostate cancer diagnosis (rate ratio 1.22 at 7 years), indicating substantial overdiagnosis of tumors that likely would not have caused harm during a man’s lifetime.

⚠️ Major Criticism and Flaws

Subsequent analyses revealed severe flaws that made the original results largely uninterpretable. The primary issue was “contamination” of the control group.

• Extensive Screening in the Control Group: Up to 90% of men in the control group underwent at least one PSA test during the trial period. In later years, this group actually had more PSA tests than the screening group.

• Baseline Testing: Over 40% of men in both groups had already received a PSA test before the trial even began.

• Conclusion: This means the trial did not compare “screening vs. no screening,” but rather “annual screening vs. opportunistic screening.” Consequently, the PLCO is now widely considered an invalid comparison for evaluating the efficacy of PSA screening.

🔬 Subsequent Research and Legacy

Despite its flaws, the PLCO trial remains a rich source of data for ongoing research that aims to improve cancer screening.

• Biomarker Development: The biological samples collected are still being analyzed. A 2023 study using PLCO data found that adding percent free PSA (%fPSA) to total PSA significantly improved the prediction of clinically significant and fatal prostate cancers, particularly in men with a total PSA between 2-10 ng/mL.

• Risk Modeling: Data from the trial has been used to create new prediction models to estimate an individual’s long-term risk of prostate cancer mortality following a screening test.

In summary, while the PLCO trial initially suggested no benefit to PSA screening, this conclusion is now considered invalid due to high rates of screening in the control group. The trial’s true legacy is shifting the focus from whether to screen to how to screen more intelligently, using risk-stratified approaches to maximize benefits and minimize harms like overdiagnosis.

Quantifying Contamination: Analyses showed ~80-90% of the “unscreened” control group actually had PSA tests, rendering the original comparison invalid .
Adjusting for Contamination: Statistical models that account for this suggest screening may reduce prostate cancer mortality by 47-72% .

PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) – DRE Trends Analysis

Journal/Author: Research and Reports in Urology (Guan K, et al., 2025)

Design: Secondary analysis of the PLCO randomized controlled trial.

Population: 34,756 men (1,713 Black, 33,043 White) with serial digital rectal examinations (DRE) over 10 years.

Primary Outcome: Odds of suspicious DRE as diagnosis approaches.

• Result: 23.0% increase per year closer to diagnosis (OR 1.230; 95% CI 1.193-1.268).

Key Secondary Outcomes:

• Positive predictive value of suspicious DRE: 4.74% at 10 years prior, 36.82% at 5 years, 60.63% at 2 years, 90.48% at diagnosis.

• Non-suspicious DRE: 5.2% increase per year closer to diagnosis (OR 1.052).

Conclusion: The probability of a suspicious DRE finding increases significantly as the time of prostate cancer diagnosis approaches, suggesting a potential role in risk-based screening strategies.

Limitations: Retrospective analysis; cannot account for verification bias; DRE subjective; modern practice incorporates MRI and biomarkers; no mortality reduction data.

🔬 FOUNDATIONAL MRI TRIALS: ESTABLISHING THE PARADIGM

PROMIS Trial (Prostate MRI Imaging Study)

Journal/Author: The Lancet (Ahmed HU, et al., 2017); ISRCTN Registry (ISRCTN16082556)

Design: Prospective, multicenter, paired-cohort confirmatory study conducted at multiple UK institutions between 2012 and 2015. The study was designed to determine whether multiparametric MRI (mpMRI) could replace transrectal ultrasound (TRUS)-guided biopsy as the initial diagnostic test for men at risk of prostate cancer .

Population: 576 men with elevated PSA and no prior biopsy. All participants underwent mpMRI followed by combined transrectal-transperineal template mapping (TPM) biopsies at 5 mm intervals, resulting in one of the most extensively characterised prostate cancer diagnosis cohorts in existence .

Key Findings:

• Sensitivity: MRI detected 93% of clinically significant cancers (defined as Gleason ≥4+3 or cancer core length ≥6mm).

• Negative Predictive Value (NPV): 89% for ruling out clinically significant cancer.

• Biopsy Avoidance: 27% of men could safely avoid biopsy if MRI was negative.

• TRUS biopsy performance: TRUS biopsy missed 52% of clinically significant cancers detected by TPM biopsy.

Conclusion: This unique, never-to-be-repeated study was the first to prove that MRI is a superior test for prostate cancer detection compared to standard transrectal biopsy . It demonstrated that MRI could be used to triage men with elevated PSA, potentially avoiding about one-quarter of biopsies.

Take-home Message: PROMIS established that MRI should precede biopsy in the diagnostic pathway. Men with negative MRI can safely avoid immediate biopsy, while those with suspicious lesions require targeted biopsy. This study fundamentally changed the diagnostic approach to prostate cancer worldwide.

Limitations: TPM biopsy (the reference standard) is invasive and not routinely used in clinical practice. The study did not assess MRI-targeted biopsy directly—it compared MRI as a triage test followed by systematic biopsy in all men.

Ongoing Follow-up: The PROMIS digital pathology extension (2024-2029) is now retrieving all biopsy slides for digitization and linking to clinical outcomes to test whether baseline clinical, MRI, and digital pathology features can predict cancer progression or death .

PRECISION Trial (Prostate Evaluation for Clinically Important Disease: Sampling Using Image Guidance or Not)

Journal/Author: New England Journal of Medicine (Kasivisvanathan V, et al., 2018); Urology Times

Design: Phase 3, multicenter, randomized controlled trial conducted at 25 centers in 11 countries. The study compared MRI-targeted biopsy versus standard TRUS-guided biopsy in biopsy-naïve men with suspected prostate cancer .

Population: 500 men with elevated PSA or abnormal digital rectal exam. Patients were randomized to:

• MRI arm: Multiparametric MRI with or without targeted biopsy (biopsy performed only if MRI was suspicious)

• Standard arm: Systematic 10-12 core TRUS-guided biopsy

Primary Outcome: Detection of clinically significant prostate cancer (csPCa; Gleason ≥3+4).

• Result: MRI arm detected csPCa in 38% vs. 28% in TRUS arm (p=0.005) .

Key Secondary Outcomes:

• Clinically insignificant cancer detection: 9% in MRI arm vs. 22% in TRUS arm (adjusted difference -13 percentage points; p<0.001) .

• Biopsy avoidance: 28% of men in MRI arm had negative MRI and avoided biopsy entirely.

• Safety: The MRI pathway reduced unnecessary biopsies and overdiagnosis of indolent cancers.

Conclusion: MRI with targeted biopsy detected more clinically significant cancers and fewer insignificant cancers compared to standard TRUS biopsy. This provided level 1 evidence that MRI should be incorporated into the diagnostic pathway .

Take-home Message: For men with suspected prostate cancer, performing MRI before biopsy and targeting suspicious lesions improves diagnostic accuracy, reduces overdiagnosis, and allows a substantial proportion to avoid biopsy altogether. This study, along with PROMIS, changed international guidelines.

Limitations: Moderate agreement between site radiologists and central review (78%), highlighting the need for standardized image quality and reporting. Long-term follow-up outcomes for men with negative MRI are still maturing.

PRECISE Trial (MRI-Targeted Biopsy Confirmation Study)

Design: A companion trial to PRECISION, PRECISE was designed to confirm the noninferiority of the MRI pathway in different healthcare settings.

Key Findings: PRECISE demonstrated noninferiority of MRI-targeted biopsy compared to systematic biopsy, reinforcing the PRECISION results and expanding the evidence base to broader populations .

🔬 OPTIMIZING MRI: BIPARAMETRIC VS. MULTIPARAMETRIC

PRIME Trial (Prostate Imaging using MRI ± Contrast Enhancement)

Journal/Author: JAMA (Ng ABCD, Asif A, Agarwal R, et al., 2025); Urology Times ; Renal and Urology News

Design: Prospective, multicenter, international diagnostic clinical trial conducted across 12 countries. The study aimed to determine whether biparametric MRI (bpMRI), which omits the dynamic contrast-enhanced (DCE) sequence, is noninferior to multiparametric MRI (mpMRI) for detecting clinically significant prostate cancer .

Population: 555 men with clinical suspicion for prostate cancer. Median age 65 years, median PSA 5.6 ng/mL, and 12.7% had abnormal digital rectal examination findings. All patients underwent both bpMRI and mpMRI followed by biopsy. Radiologists were initially blinded to DCE sequences and graded suspicious areas using Likert and PI-RADS v2.1 scoring systems .

Primary Outcome: Detection of Gleason Grade Group ≥2 prostate cancer.

• bpMRI: 29.2%

• mpMRI: 29.6%

• Difference: 0.4% – noninferiority demonstrated (P=0.50) .

Key Secondary Outcomes:

• Clinically insignificant cancer detection: 9.2% (bpMRI) vs. 9.6% (mpMRI) .

• Diagnostic quality: 99% of scans deemed adequate for diagnosis .

• DCE-specific findings: DCE sequences identified newly suspicious areas in 6.3% of patients, but 93.5% had no additional detection of csPCa after biopsy of these areas .

• Sensitivity/Specificity:

  • bpMRI: 98.0% sensitivity, 61.6% specificity

  • mpMRI: 99.3% sensitivity, 60.1% specificity

• PPV/NPV:

  • bpMRI: 53.1% PPV, 98.6% NPV

  • mpMRI: 52.5% PPV, 99.5% NPV

• Clinical impact: Blinded multidisciplinary team assessment found added value of DCE in only 4.3% of patients .

Conclusion: Biparametric MRI performs as well as multiparametric MRI for diagnosis of clinically significant prostate cancer, providing level-1 evidence that bpMRI could be an alternative first-line diagnostic test. The omission of contrast reduces scan time from approximately 40 minutes to 20 minutes, eliminates contrast toxicity and cannulation risks, improves scanner throughput, and reduces environmental impact .

Take-home Message: For centers with high-quality MRI scanners (<10 years old) and experienced radiologists, biparametric MRI is a new standard of care in the primary diagnostic setting. The significant practical benefits—faster scans, lower cost, and greater accessibility—can help address the global gap in prostate MRI access, where only about one-third of biopsy-naïve men currently receive MRI before biopsy .

Limitations: Only 2 patients in the entire trial had csPCa detected solely due to DCE sequences. The findings require that centers ensure adequate image quality through rigorous quality assurance using PI-QUAL scoring and adherence to PI-RADS standards before adopting a bpMRI approach .

Editorial Commentary: In an accompanying editorial, Davenport, Pockros, and Morgan noted that the PRIME trial provides “compelling evidence to update the standard of care in the diagnostic evaluation of prostate cancer” .

🔬 MICRO-ULTRASOUND (MICROUS): A DISRUPTIVE TECHNOLOGY

OPTIMUM Trial (Micro-Ultrasound vs. MRI for Prostate Cancer Diagnosis)

Journal/Author: JAMA (Klotz L, et al., 2025); RSNA Daily Bulletin ; EAU Uroweb

Design: Open-label, randomized noninferiority trial—the largest clinical trial of micro-ultrasound technology to date. Conducted across 20 centers in 8 countries .

Technology Background: Micro-ultrasound operates at 29 MHz with 70-micron resolution, offering approximately three times greater resolution than conventional ultrasound. It allows real-time visualization of changes in the prostate’s cellular and ductal architecture associated with cancer. There are currently more than 300 microUS systems in use globally, with more than 150,000 procedures performed .

Population: 678 biopsy-naïve men aged 59-71 years with elevated PSA and/or abnormal DRE, no history of genitourinary cancer. Patients were randomized into three groups :

1. microUS-guided biopsy alone

2. microUS plus mpMRI-guided biopsy using microUS

3. mpMRI/conventional US fusion-guided biopsy

All groups underwent targeted biopsies guided by their assigned imaging modality, followed by synchronous systematic biopsies.

Primary Outcome: Detection of Gleason Grade Group ≥2 prostate cancer.

• Difference between microUS and mpMRI/conventional US fusion: 3.5% (95% CI -4% to 10.9%)

• Noninferiority p-value: 0.0026 – noninferiority demonstrated .

Key Secondary Outcomes:

• Detection rate: MicroUS-guided biopsy actually had a slightly higher (though not statistically superior) csPCa detection rate than mpMRI fusion—about 3.5% higher. This was surprising given that guidance on recognizing anterior cancers on microUS was only released partway through the study .

• Robustness: The conclusion was robust across variations in csPCa definition, biopsy approach, and biopsy route .

Conclusion: MicroUS-guided prostate biopsy is a noninferior alternative to mpMRI/conventional US fusion-guided biopsy for clinically significant prostate cancer detection. It can provide faster and more affordable care .

Take-home Message: Clinicians should consider microUS-guided biopsy as a valuable tool for both risk stratification and biopsy, particularly in settings where mpMRI is logistically challenging, where patient factors (claustrophobia, implanted devices, renal impairment) make MRI difficult, or where avoiding an extra procedure is preferable. MicroUS offers a “one-stop-shop” for diagnosis without the complexity or cost of MRI .

Practical Benefits :

• Cheaper and more accessible, especially in settings with limited MRI availability

• No need for contrast agents like gadolinium

• Can be performed in a single visit, eliminating multiple hospital appointments

• Easier to learn and interpret for trained urologists

• Can be used in conjunction with mpMRI through elastic fusion to improve sampling of MRI targets

Limitations: MRI remains superior for evaluating extraprostatic extension (ECE). Systematic biopsy remains essential—relying on imaging alone risks missing clinically significant cancers, particularly anterior and small-volume disease .

Expert Commentary: Prof. Laurence Klotz (CA), lead investigator, stated: “This is game-changing. We’re talking about a one-stop-shop for diagnosis without the complexity or cost of MRI.” Prof. Jochen Walz (FR) added: “MicroUS could make targeted prostate biopsies safer and more accessible – particularly in under-resourced health systems” .

Whole-Mount Correlation Study (Micro-US, MRI, and PSMA PET)

Journal/Author: Grand Rounds in Urology (Brisbane WG, et al., WSAUA 2025)

Design: Prospective comparison study using whole-mount prostatectomy specimens as the reference standard. This study extends the OPTIMUM findings by validating imaging accuracy against histopathology rather than biopsy .

Population: 68 evaluable patients undergoing prostatectomy with available MRI, micro-ultrasound, and in a subset, PSMA PET imaging. About one-third had ≥T3 disease, allowing assessment of extracapsular extension (ECE) .

Methods: Expert reviewers (radiologist for MRI, urologist for microUS, nuclear medicine physician for PSMA) independently contoured lesions. A pathologist mapped whole-mount sections. All imaging and pathology were aligned to a 39-sector prostate map for sector-by-sector comparison .

Key Findings :

• Index Lesions: Micro-ultrasound and MRI both achieved ~90% detection—no statistical difference.

• All Grade Group ≥2 Lesions: ~78% accuracy for both modalities.

• Anterior Tumors: Slight numerical advantage for MRI, but not statistically significant.

• ECE Detection: MRI outperformed micro-ultrasound for detecting extraprostatic extension.

• PSMA PET Subset: Showed similar index and Grade Group ≥2 detection (high 90s and 70s, respectively), but performance for anterior and small lesions was unexpectedly modest—possibly due to sample variation.

Conclusion: Micro-ultrasound ≈ MRI for detecting clinically significant intraprostatic lesions, consistent with OPTIMUM. MRI remains superior for evaluating ECE. PSMA PET adds complementary information but did not outperform MRI or microUS in this surgical cohort .

Take-home Message: For focal therapy planning, relying on imaging alone risks missing clinically significant cancers. Systematic biopsy remains essential. Micro-US may serve as a real-time, lower-cost alternative to MRI for lesion targeting, but MRI is still needed when accurate staging (ECE assessment) is critical.

Environmental Impact Consideration

Journal/Author: JAMA (Letter to the Editor, 2025)

Context: A letter responding to the OPTIMUM trial highlighted important environmental considerations. Life-cycle assessments have reported mean CO₂ equivalent emissions of 17.5 kg per scan for MRI vs. 0.5 kg per scan for ultrasonography .

Implication: Given the impact of healthcare on the environment and downstream implications for human health, the OPTIMUM trial findings should be considered through this lens. The potentially substantial environmental impact of MRI-based prostate cancer screening makes microUS an attractive alternative from a sustainability perspective .

🔬 META-ANALYSES: SYNTHESIZING THE EVIDENCE

VISION Study (Individual Patient Data Meta-Analysis)

Journal/Author: European Urology (Kasivisvanathan V, Wai-Shun Chan V, Clement KD, et al., 2024)

Design: Individual patient data meta-analysis (IPDMA) comparing MRI-targeted biopsy (±TB) with standard TRUS-guided biopsy for prostate cancer diagnosis. The study included data from the PRECISION and PRECISE trials .

Population: 953 patients from two randomized controlled trials of biopsy-naïve men with clinical suspicion of prostate cancer. Studies were included if participants with suspicious MRI underwent targeted biopsy alone and those with nonsuspicious lesions avoided biopsy .

Primary Outcome: Proportion of men diagnosed with clinically significant prostate cancer (csPCa; Gleason ≥3+4).

• Result: MRI ± TB detected 8.7 percentage points (36.3% vs. 27.6%; 95% CI 2.8-14.6, p=0.004) more csPCa than TRUS biopsy .

Key Secondary Outcomes:

• Biopsy avoidance: 32.2% of patients in the MRI arm avoided biopsy due to nonsuspicious MRI .

• Clinically insignificant cancer detection: MRI ± TB detected 12.3 percentage points (9.6% vs. 21.9%; 95% CI 7.8-16.9, p<0.001) less insignificant cancer (Gleason 3+3) .

• Risk of bias: The overall risk of bias for included studies was low after assessment using QUADAS-2, QUADAS-C, and ROB 2.0 tools .

Conclusion: The MRI ± TB pathway is superior to TRUS biopsy in detecting clinically significant prostate cancer and avoiding the diagnosis of clinically insignificant cancer. MRI should be included in the standard of care pathway for prostate cancer diagnosis .

Take-home Message: This meta-analysis provides the highest level of evidence supporting the MRI-targeted pathway. The findings strongly support the routine use of MRI in the standard prostate cancer diagnostic pathway, with the ability to avoid biopsy in nearly one-third of men.

📊 SUMMARY OF KEY THERAPEUTIC SHIFTS IN PROSTATE CANCER IMAGING

🩻 ACTIVE SURVEILLANCE

ProtecT Trial (Prostate Testing for Cancer and Treatment) – 15-Year Follow-up

Journal/Author: New England Journal of Medicine (Hamdy FC, et al., 2023); Urologia (Terlizzi M, et al., 2024)

Design: Randomized trial comparing active monitoring, radical prostatectomy, and radiotherapy.

Population: 1,643 men with screen-detected localized prostate cancer; 82,559 men underwent PSA testing; 3.5% were diagnosed with prostate cancer.

Primary Outcome: Prostate cancer-specific mortality.

• Result: 1.5-2.2 per 1,000 person-years across all treatment groups. No significant difference among groups.

Key Secondary Outcomes:

• Metastatic disease: Twice as likely in the active monitoring group (excess of 3.5 more diagnoses per 1,000 person-years).

• Avoidance of radical treatment: Approximately 40% of men avoided radiotherapy or surgery by 15 years.

• Conversion to treatment: 30% at 3 years, 55% at 10 years, 65% at 15 years.

Conclusion: Active monitoring avoids immediate treatment in most men without compromising cancer-specific survival at 15 years, though metastasis risk is higher. Modern active surveillance with MRI and serial biopsies is the preferred approach for low-risk disease.

Limitations: “Active monitoring” protocol was less intensive than modern active surveillance (no mandatory serial biopsies); 15-year follow-up insufficient as many deaths occur after 15 years; conducted in pre-MRI era; 99% white ethnic origin limits generalizability.

GÖTEBORG-1 Screening Trial – 25-Year Active Surveillance Outcomes

Journal/Author: European Urology (Hugosson J, et al., 2025)

Design: Prospective population-based screening trial with long-term follow-up.

Population: 488 men with screen-detected prostate cancer managed with active surveillance (251 very low-risk, 129 low-risk, 108 intermediate-risk); median follow-up 18 years.

Primary Outcome: Prostate cancer-specific survival at 25 years.

• Result: 94% for the entire cohort.

Key Secondary Outcomes:

• Treatment-free survival at 22 years: 38% overall.

• By risk group at 19 years: Very low-risk 55%, low-risk 35%, intermediate-risk 30%.

• Failure-free survival at 22 years: 68%.

• Prostate cancer-specific survival at 24 years by risk group: Very low-risk 99%, low-risk 92%, intermediate-risk 85%.

Conclusion: With 25-year follow-up, active surveillance is confirmed as a safe and effective strategy for appropriately selected men, though lifelong monitoring is essential as progression risk persists over decades.

Limitations: No predefined active surveillance protocol; risk of failure increased over time, highlighting need for lifelong monitoring; observational design without control arm.

🏥 LOCALIZED DISEASE: RADICAL PROSTATECTOMY

SPCG-4 (Scandinavian Prostate Cancer Group Study Number 4) – 30-Year Follow-up

Journal/Author: European Urology (Holmberg L, et al., 2025)

Design: Randomized trial comparing radical prostatectomy (RP) versus watchful waiting (WW).

Population: 695 men with early prostate cancer (1989-1999); aged <75 years with life expectancy >10 years; mean PSA 13.0; 60% Gleason 2-6, 28% Gleason 7-10; 11% T1, 75% T2.

Primary Outcome: Prostate cancer-specific mortality at 30 years.

• Result: RP 25.9% vs. WW 42.9%; absolute risk reduction (ARR): 17.0%; number needed to treat (NNT): 6.

• NNT decreased from 58 at 5 years to 6 at 30 years.

Key Secondary Outcomes:

• Overall mortality at 30 years: RP 92.4% vs. WW 98.3%; ARR 5.9%.

• Life-years gained: Evident after conditioning on 20-year survival.

• Benefit by risk group: Negligible for low-risk (Gleason grade group 1) patients.

Conclusion: Radical prostatectomy reduces prostate cancer mortality compared to watchful waiting, but the absolute benefit is time-dependent—taking nearly two decades to emerge—and is negligible for low-risk disease.

Limitations: Pre-PSA era; only 12% had nonpalpable T1c tumors; 15% of WW arm received curative treatment (contamination); only 85% of RP arm actually underwent surgery; limited generalizability to screen-detected contemporary patients; older grading systems used.

PIVOT (Prostate Cancer Intervention Versus Observation Trial) – 20-Year Follow-up

Journal/Author: New England Journal of Medicine (Wilt TJ, et al., 2017)

Design: Randomized trial comparing radical prostatectomy (RP) versus observation.

Population: 731 men with localized prostate cancer; mean PSA 10.1; 62% white; 74% Gleason 2-6; 50% T1, 40% T2.

Primary Outcome: All-cause mortality.

• Result: RP 61% vs. Observation 67%; HR 0.84 (95% CI 0.70-1.01; P=0.06)—narrowly missed statistical significance.

Key Secondary Outcomes:

• Prostate cancer-specific mortality: RP 7.4% vs. Observation 11.4%; HR 0.63 (95% CI 0.39-1.02; P=0.06).

• Subgroup findings: Intermediate-risk patients appeared to benefit; low-risk and high-risk patients did not.

Conclusion: In a predominantly low-risk population with significant competing mortality, radical prostatectomy did not significantly reduce all-cause or prostate cancer-specific mortality compared to observation.

Limitations: Primary outcome narrowly missed statistical significance; high rate of competing mortality in older, sicker population; substantial cross-over and non-adherence; limited power for subgroup analyses; underpowered for long-term outcomes.

🔬 LOCALIZED DISEASE: RADIOTHERAPY WITH ADT

EORTC 22863 (RT +/- Long-term ADT)

Journal/Author: Lancet (Bolla M, et al., 2002); European Urology (Zurlo A, et al., 2002)

Design: Phase 3 randomized trial comparing radiotherapy (RT) alone versus RT plus 3 years of androgen deprivation therapy (ADT).

Population: 415 men with high-risk localized prostate cancer; 405 evaluable for toxicity.

Primary Outcome: Overall survival.

• Result: Significantly improved with ADT (HR 0.51; 95% CI 0.36-0.73).

Key Secondary Outcomes:

• Disease-free survival: HR 0.34 (95% CI 0.24-0.47).

• Acute toxicity (WHO grade 3-4): 15% moderate-severe.

• Life-threatening toxicity: 6 cases (1.5%).

• Age, prior surgery, radiation dose predictive of toxicity.

• No increase in toxicity with combined hormone therapy.

Conclusion: Adding 3 years of ADT to radiotherapy significantly improves overall survival in high-risk localized prostate cancer, establishing combined modality therapy as the standard of care.

Limitations: Long-term ADT side effects (cardiovascular, metabolic) not fully captured; pre-date modern RT techniques (3D-CRT/IMRT); optimal ADT duration now questioned; conventional RT doses used.

EORTC 22961 (Short vs. Long ADT with RT)

Journal/Author: IAEA Translation (original EORTC publication); Hindawi Table 3

Design: Non-inferiority randomized trial comparing 6 months of ADT (SADT) versus 2.5 years of ADT (LADT) with radiotherapy.

Population: 970 men with locally advanced prostate cancer (T1c-4 N0-2 M0, PSA <150 ng/mL).

Primary Outcome: Overall survival at 5 years (non-inferiority margin HR = 1.35 for SADT vs. LADT).

• Result: LADT 85.3% vs. SADT 80.6%; HR 1.43 (96.4% CI 1.04-1.98)—failed to prove non-inferiority.

Key Secondary Outcomes:

• 5-year clinical PFS: LADT 81.8% vs. SADT 68.9%; HR 1.93.

• 5-year biochemical PFS: LADT 78.3% vs. SADT 58.9%; HR 2.29.

• Progression (mostly biochemical/bone): 159 on SADT vs. 61 on LADT.

Conclusion: Six months of ADT with radiotherapy is inferior to 2.5 years of ADT; longer-duration ADT remains necessary for optimal disease control in locally advanced disease.

Limitations: Study stopped early at interim analysis; non-inferiority could not be confirmed; QoL and metabolic outcomes not fully reported.

RTOG 92-02 (Long-term ADT Duration)

Journal/Author: Hindawi Table 3; ecancer/ASTRO (Lawton C, 2015)

Design: Phase 3 randomized trial comparing radiotherapy plus 4 months of ADT versus radiotherapy plus 28 months of ADT.

Population: 1,514 patients with locally advanced prostate cancer (T2c-T4); median follow-up 11.3 years.

Primary Outcome: 10-year overall survival.

• Result: 52% vs. 54%—not statistically significant.

Key Secondary Outcomes:

• 10-year disease-specific survival: 84% vs. 89% (p<0.001)—significant improvement with long-term ADT.

• Gleason 8-10 subset: 10-year OS 32% vs. 45% (p<0.001).

• Grade 3 GI toxicity at 8 years: 2.9% vs. 1.2%.

Conclusion: Long-term ADT improves disease-specific survival and, in high-grade subsets, overall survival, confirming that patients with aggressive disease benefit from extended hormone therapy despite the lack of OS benefit in the overall cohort.

Limitations: Long-term ADT side effects (weight gain, muscle loss, bone loss) require mitigation with exercise and diet; confirms longer is better; optimal duration remains to be defined (18 vs. 36 months).

🎯 ADJUVANT VS SALVAGE RADIOTHERAPY (POST-PROSTATECTOMY)

RADICALS-RT (Timing of Radiotherapy)

Journal/Author: Annals of Oncology (Parker CC, et al., 2024); The Lancet (primary publication)

Design: Phase 3 randomized trial comparing adjuvant radiotherapy versus observation with salvage radiotherapy for PSA failure after radical prostatectomy.

Population: 1,396 patients post-prostatectomy with at least one risk factor (pT3/4, Gleason 7-10, positive margins, pre-operative PSA ≥10 ng/mL); post-operative PSA ≤0.2 ng/mL at randomization.

Primary Outcome: 10-year freedom from distant metastasis (FFDM).

• Result: Adjuvant RT 93% vs. Salvage RT 90%; HR 0.68 (95% CI 0.43-1.07; p=0.095)—NOT SIGNIFICANT.

Key Secondary Outcomes:

• 10-year overall survival: 88% vs. 87% (HR 0.98; p=0.92).

• Biochemical PFS: Significantly improved with Adjuvant RT but not primary endpoint.

• Urinary incontinence at 1 year: Worse with Adjuvant RT (p=0.001).

• Fecal incontinence: Remained significant at 10 years (p=0.017).

• Salvage RT received: Only 39% of observation group received RT during follow-up.

Conclusion: Adjuvant radiotherapy does not improve metastasis-free or overall survival compared to observation with salvage RT for PSA failure, but increases urinary and bowel morbidity. Observation with salvage RT for biochemical recurrence should be the standard of care after radical prostatectomy.

Limitations: Largest trial addressing timing question; 10-year FFDM events low overall (80 events), limiting power; only 39% of salvage arm received RT, suggesting many patients avoid RT entirely.

RTOG 9601 (Salvage RT ± Antiandrogen)

Journal/Author: International Journal of Radiation Oncology, Biology, Physics (Lukka HR, et al., 2025)

Design: Phase 3 double-blind randomized trial comparing salvage radiotherapy plus placebo versus salvage radiotherapy plus 24 months of bicalutamide (150 mg/d).

Population: 760 post-prostatectomy patients with pT3N0 or pT2N0 + positive margins; PSA 0.2-4.0 ng/mL at entry; enrolled 1998-2003.

Primary Outcome: 18-year overall survival.

• Result: RT + antiandrogen 53% vs. RT + placebo 43%; adjusted HR 0.82 (95% CI 0.67-1.00; 1-sided p=0.025).

Key Secondary Outcomes:

• 18-year prostate cancer death: 18% vs. 28% (sHR 0.63; p=0.002).

• 18-year metastatic prostate cancer: 22% vs. 31% (sHR 0.62; p=0.001).

• OS benefit at 12 years: 5% absolute.

• OS benefit at 18 years: 9.8% absolute.

Conclusion: Adding 24 months of bicalutamide to salvage radiotherapy significantly improves long-term overall survival, with the absolute benefit increasing from 5% at 12 years to 9.8% at 18 years. Patients with pre-RT PSA >0.6 ng/mL derive the greatest benefit.

Limitations: Longest follow-up of any salvage RT trial (median 18.9 years). Only RCT demonstrating OS benefit from adding hormone therapy to salvage RT. Uses bicalutamide (not traditional ADT) for 24 months.

GETUG-AFU 16 (Salvage RT ± Short ADT)

Journal/Author: Lancet Oncology (Carrie C, et al., 2019)

Design: Phase 3 open-label randomized trial comparing salvage radiotherapy alone versus salvage radiotherapy plus 6 months of goserelin.

Population: 743 patients post-prostatectomy with PSA 0.2-2.0 ng/mL; no evidence of metastatic disease; enrolled 2006-2010.

Primary Outcome: 10-year progression-free survival.

• Result: RT+ADT 64% vs. RT alone 49%; HR 0.54 (95% CI 0.43-0.68; p<0.0001).

Key Secondary Outcomes:

• Metastasis-free survival: 6% absolute improvement at 5 and 10 years (post-hoc analysis).

• Overall survival: No significant difference (immature data).

• Late serious adverse events: No treatment-related deaths; two secondary cancers reported (not treatment-related).

Conclusion: Adding 6 months of ADT to salvage radiotherapy significantly improves progression-free survival and metastasis-free survival, though overall survival benefit has not yet been demonstrated; short-course ADT should be considered for patients with biochemical recurrence.

Limitations: PFS benefit clearly demonstrated, but OS benefit not yet shown. Lower pre-sRT PSA (median 0.3 ng/mL) than RTOG 9601. No OS benefit in meta-analysis combining all 4 trials.

RADICALS-HD (ADT Duration with Postoperative RT)

Journal/Author: The Lancet (Parker CC, et al., 2024)

Design: Phase 3 randomized trial with two comparisons: (1) No ADT vs. 6 months ADT; (2) 6 months vs. 24 months ADT with postoperative radiotherapy.

Population: 2,839 patients with indication for postoperative radiotherapy; PSA <5 ng/mL; absence of metastases; enrolled 2007-2015.

Primary Outcome: 10-year metastasis-free survival (MFS).

Results – Comparison 1 (6 months vs. none):

• 10-year MFS: 80.4% vs. 79.2%; HR 0.886 (95% CI 0.688-1.140; p=0.35)—NO BENEFIT.

Results – Comparison 2 (24 months vs. 6 months):

• 10-year MFS: 78.1% vs. 71.9%; HR 0.67—SIGNIFICANT.

Key Secondary Outcomes:

• Grade ≥3 toxicity: No ADT 17%, 6 months ADT 14%, 24 months ADT 19%.

• No treatment-related deaths.

Conclusion: Six months of ADT provides no benefit when added to postoperative radiotherapy; 24 months of ADT improves metastasis-free survival compared to 6 months, but the benefit is modest and must be balanced against toxicity. Shared decision-making based on individual risk and tolerance of side effects is essential.

Limitations: Largest trial of ADT with postoperative RT. First comparison (6 mo vs none) negative—does not support short-course ADT. Second comparison (24 mo vs 6 mo) positive—longer duration improves MFS. Median PSA low (0.2 ng/mL), may explain lack of benefit in 6 mo comparison.

🎯 OLIGOMETASTATIC DISEASE

STAMPEDE (M1|RT) – Radiotherapy to the Prostate

Journal/Author: PLoS Medicine (Parker CC, James ND, et al., 2022); initial report Lancet 2018

Design: Phase 3 randomized controlled trial with 1:1 randomization to standard of care (SOC) versus SOC plus prostate radiotherapy.

Population: 2,061 men with newly diagnosed metastatic prostate cancer; 1,939 had metastatic burden classifiable (42% low burden, 58% high burden).

Primary Outcome: Overall survival (OS) by metastatic burden.

• Low-burden: HR 0.64 (95% CI 0.52-0.79; p<0.001)—significant improvement.

• High-burden: HR 1.11 (95% CI 0.96-1.28; p=0.164)—no benefit.

• Interaction p<0.001.

Key Secondary Outcomes:

• Failure-Free Survival: HR 0.76 (p<0.0001) favoring RT arm.

• 3-year OS (low-burden): 81% (RT) vs. 73% (SOC).

• Symptomatic local events: No difference.

• QoL: No detriment in global QoL or summary scores.

• Toxicity: Long-term grade ≥3 urinary toxicity: 10 vs. 10; bowel toxicity: 11 vs. 15.

Conclusion: Prostate radiotherapy improves overall survival in men with low-volume metastatic hormone-sensitive prostate cancer and should be standard of care alongside systemic therapy.

Limitations: Only 18% received docetaxel; none received next-gen ARPIs (abiraterone, enzalutamide)—now standard of care; conventional imaging used (not PSMA PET), which may underestimate disease burden; open-label design; low-burden definition (≤3 mets) based on conventional imaging may shift with molecular imaging, risking “Will Rogers effect”; RT dose (55 Gy/20f or 36 Gy/6f) lower than standard radical doses for localized disease.

STOMP (Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence)

Journal/Author: Journal of Clinical Oncology (Ost P, et al., 2020)

Design: Multicenter randomized phase II trial comparing metastasis-directed therapy (MDT – surgery or SBRT) versus surveillance.

Population: 62 patients with biochemical recurrence after primary curative treatment, ≤3 extracranial metastases on choline PET-CT, testosterone >50 ng/mL.

Primary Outcome: Androgen deprivation therapy (ADT)-free survival at 5 years.

• Result: MDT 34% vs. Surveillance 8%; HR 0.57 (80% CI 0.38-0.84; p=0.06)*.

• *p-values deemed significant at <0.20 per protocol.

Key Secondary Outcomes:

• CRPC-free survival at 5 years: MDT 76% vs. Surveillance 53%; HR 0.62 (80% CI 0.35-1.09; p=0.27).

• Overall survival at 5 years: 85% overall; 6/14 deaths attributed to prostate cancer.

Conclusion: Metastasis-directed therapy with SBRT or surgery significantly delays the need for ADT in oligorecurrent prostate cancer, supporting its use in appropriately selected patients.

Limitations: Phase II design with small sample size; relies on choline PET (lower sensitivity than PSMA); heterogeneity in MDT modalities; short follow-up relative to disease natural history.

ORIOLE (Oligometastasis-Directed Therapy for Prostate Cancer)

Journal/Author: Journal of Clinical Oncology (Phillips R, et al., 2020)

Design: Phase 2 randomized, non-blinded trial comparing stereotactic body radiotherapy (SBRT) versus observation.

Population: 54 men with oligometastatic (≤3 metastases) hormone-sensitive prostate cancer.

Primary Outcome: Progression at 6 months.

• Result: SBRT 19% vs. Observation 61%.

Key Secondary Outcomes:

• Median progression-free survival: Significantly improved with SBRT.

• Patterns of progression: Favorable with SBRT, with evidence of immune-mediated abscopal effects in some patients.

Conclusion: SBRT significantly reduces disease progression at 6 months in oligometastatic hormone-sensitive prostate cancer, with evidence of immune-mediated abscopal effects in some patients.

Limitations: Very small sample size; short follow-up; surrogate primary endpoint (progression, not survival); single-institution study; heterogeneity in metastatic sites.

RAMPP Trial (Radical Prostatectomy + Best Systemic Therapy vs. Best Systemic Therapy Alone)

Journal/Author: European Urology (Graefen M, et al., 2025)

Design: Phase 3 randomized controlled trial comparing radical prostatectomy plus best systemic therapy versus best systemic therapy alone.

Population: 132 men with oligometastatic prostate cancer (1-5 bone metastases ± nodes) on conventional or PET imaging; randomized 1:1.

Primary Outcome: 5-year cancer-specific mortality (CSM).

• Result: RP+BST 13% vs. BST alone 23%; HR 0.39 (95% CI 0.16-0.98; p=0.045).

Key Secondary Outcomes:

• 5-year overall survival: 81% vs. 74% (not significant).

• Grade ≥III complications: 14% in RP arm.

• Clinical progression (including CSM): 59% vs. 60%.

Conclusion: Cytoreductive radical prostatectomy may improve cancer-specific survival in oligometastatic disease, but the lack of overall survival benefit and outdated systemic therapy limit definitive conclusions; surgery should remain investigational in this setting.

Limitations: Trial stopped early due to change in medical practice (STAMPEDE results made no-local-treatment arm unethical); OS benefit not statistically significant; “best systemic therapy” outdated—few received intensified hormonal therapy, inconsistent docetaxel use; only 30% staged with PSMA PET; 60% had positive margins or lymph node invasion at pathology.

🔬 METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (mHSPC)

CHAARTED/E3805 (ADT +/- Docetaxel)

Journal/Author: New England Journal of Medicine (Sweeney CJ, et al., 2015); European Urology Oncology (Sentana-Lledo D, et al., 2025)

Design: Phase 3 randomized trial comparing ADT alone versus ADT plus docetaxel.

Population: 790 men with metastatic hormone-sensitive prostate cancer (mHSPC).

Primary Outcome: Overall survival.

• Result: ADT+docetaxel 57.6 months vs. ADT 47.0 months (HR 0.61; p<0.001).

• High-volume disease: HR 0.60.

• Low-volume disease: HR 1.04 (not significant).

Key Secondary Outcomes:

• Time to castration-resistant prostate cancer (CRPC): HR 0.49.

• PSA response: 66.7% vs. 46.3%.

• Quality of life: No detriment with docetaxel.

• Pain outcomes: Favorable with docetaxel.

Conclusion: Adding docetaxel to ADT significantly improves overall survival in men with high-volume metastatic hormone-sensitive prostate cancer, establishing doublet therapy as standard of care for fit patients.

Limitations: No stratification by novel imaging (conventional imaging only); docetaxel toxicities (neuropathy, febrile neutropenia); low-volume subgroup underpowered; high-volume definition (visceral metastases or ≥4 bone lesions with ≥1 outside axial skeleton) retrospectively applied.

LATITUDE (ADT +/- Abiraterone)

Journal/Author: New England Journal of Medicine (Fizazi K, et al., 2017); European Journal of Cancer (Roy S, et al., 2024)

Design: Phase 3 randomized trial comparing ADT alone versus ADT plus abiraterone acetate with prednisone.

Population: 1,199 men with high-risk, de novo metastatic castration-sensitive prostate cancer (≥2 of: Gleason ≥8, ≥3 bone lesions, visceral metastases).

Primary Outcome: Overall survival.

• Result: HR 0.62 (95% CI 0.51-0.76; p<0.001).

• Median OS: Not reached vs. 34.7 months.

Key Secondary Outcomes:

• Radiographic progression-free survival (rPFS): HR 0.47 (95% CI 0.39-0.57).

• Time to pain progression: HR 0.70.

• Time to PSA progression: HR 0.30.

• Time to subsequent therapy: HR 0.42.

Conclusion: Adding abiraterone to ADT significantly improves overall survival and delays disease progression in high-risk de novo metastatic hormone-sensitive prostate cancer.

Limitations: Restricted to high-risk population only (not generalizable to all mHSPC); requires prednisone (mineralocorticoid toxicity); abiraterone cost/access; no comparison to docetaxel doublet; NSAID interaction analyses post-hoc.

ARASENS (ADT + Docetaxel +/- Darolutamide – Triplet Therapy)

Journal/Author: New England Journal of Medicine (Smith MR, et al., 2022)

Design: Phase 3 randomized triplet therapy trial comparing ADT plus docetaxel versus ADT plus docetaxel plus darolutamide.

Population: 1,306 men with metastatic hormone-sensitive prostate cancer (mHSPC).

Primary Outcome: Overall survival.

• Result: HR 0.68 (95% CI 0.57-0.80; p<0.001).

• 4-year OS: 62.7% vs. 50.4%.

Key Secondary Outcomes:

• Time to CRPC: HR 0.36.

• Time to pain progression: HR 0.79.

• Subsequent therapy: HR 0.39.

• Safety: Similar adverse event rates except hypertension (6.3% vs. 4.0%).

Conclusion: Adding darolutamide to ADT and docetaxel (triplet therapy) significantly improves overall survival in mHSPC, establishing a new standard for fit patients with high-volume disease.

Limitations: No comparison to ARPI + ADT doublet (all patients received docetaxel); darolutamide cost/access; cannot determine contribution of darolutamide vs. docetaxel alone; all patients had to be fit for docetaxel.

PEACE-1 (ADT + Docetaxel +/- Abiraterone – Triplet Therapy)

Journal/Author: Lancet (Fizazi K, et al., 2022)

Design: Phase 3 randomized triplet therapy trial comparing ADT plus docetaxel versus ADT plus docetaxel plus abiraterone.

Population: 1,173 men with de novo metastatic castration-sensitive prostate cancer.

Primary Outcome: Radiographic progression-free survival (rPFS) and overall survival (OS).

• rPFS: HR 0.54 (99.9% CI 0.41-0.71; p<0.0001).

• OS: HR 0.75 (95.1% CI 0.59-0.95; p=0.017).

Key Secondary Outcomes:

• CRPC-free survival: HR 0.38.

• PSA progression: HR 0.29.

• Skeletal-related events: HR 0.70.

• Grade 3-4 adverse events: 63% vs. 52%.

Conclusion: Adding abiraterone to ADT and docetaxel improves survival in de novo mHSPC, confirming the role of triplet therapy, though at the cost of increased toxicity.

Limitations: 2×2 factorial design complexity (RT vs. no RT); added toxicity with triplet; abiraterone requires prednisone; no comparison to ARPI + ADT doublet alone; all patients received docetaxel.

TITAN (ADT +/- Apalutamide)

Journal/Author: New England Journal of Medicine (Chi KN, et al., 2019)

Design: Phase 3 randomized trial comparing ADT alone versus ADT plus apalutamide.

Population: 1,052 men with metastatic hormone-sensitive prostate cancer (mHSPC).

Primary Outcome: Overall survival at 24 months.

• Result: HR 0.67 (95% CI 0.51-0.89; p=0.005).

Key Secondary Outcomes:

• Radiographic progression-free survival (rPFS): HR 0.48 (95% CI 0.39-0.60).

• Time to CRPC: HR 0.34.

• Time to pain progression: HR 0.69.

• PSA response: 89% vs. 69%.

• Quality of life: Preserved.

Conclusion: Adding apalutamide to ADT significantly improves overall survival and radiographic progression-free survival in mHSPC, with benefits seen across all patient subgroups.

Limitations: Crossover allowed (37% of placebo received subsequent ARPI); short follow-up for OS (22.7 months median); no head-to-head vs. other ARPIs; rash (27%) and fractures (11%) notable.

ARCHES (ADT +/- Enzalutamide)

Journal/Author: Journal of Clinical Oncology (Armstrong AJ, et al., 2019)

Design: Phase 3 randomized trial comparing ADT alone versus ADT plus enzalutamide.

Population: 1,150 men with metastatic hormone-sensitive prostate cancer (mHSPC).

Primary Outcome: Radiographic progression-free survival (rPFS).

• Result: HR 0.39 (95% CI 0.30-0.50; p<0.001).

Key Secondary Outcomes:

• Time to PSA progression: HR 0.19.

• Time to first symptomatic skeletal event: HR 0.52.

• Overall survival (interim): HR 0.81 (not significant).

• Quality of life: Improved with enzalutamide.

Conclusion: Adding enzalutamide to ADT significantly improves radiographic progression-free survival and delays time to castration resistance in mHSPC, with subsequent analyses confirming overall survival benefit.

Limitations: Primary endpoint rPFS (not OS); OS data immature at initial publication; crossover allowed; fatigue (24%), hypertension (14%) significant; no comparison to other ARPIs.

PSMAddition (Pluvicto in mHSPC)

Journal/Author: *ESMO 2025 / Fierce Pharma* (Novartis)

Design: Phase 3 randomized trial comparing Pluvicto (177Lu-PSMA-617) plus standard of care (ADT + ARPI) versus standard of care alone.

Population: Patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Primary Outcome: Radiographic progression-free survival (rPFS).

• Result: 28% risk reduction (HR 0.72).

Key Secondary Outcomes:

• Overall survival trend: 16% risk reduction (immature data).

• Grade ≥3 adverse events: 50.7% vs. 43%.

Conclusion: Pluvicto added to standard of care improves radiographic progression-free survival in PSMA-positive mHSPC, though the benefit is modest; overall survival data are immature and longer follow-up is needed.

Limitations: Magnitude less impressive than in mCRPC (PSMAfore HR 0.41) or historical ARPI trials (ARCHES HR 0.39); continence/sexual function concerns but not seen in safety data; immature OS; could double eligible population if approved.

CAPItello-281 (AKT Inhibitor in PTEN-Deficient mHSPC)

Journal/Author: *ESMO 2025 / Fierce Pharma* (AstraZeneca)

Design: Phase 3 randomized trial comparing capivasertib (Truqap) plus abiraterone and ADT versus abiraterone and ADT alone.

Population: Patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer.

Primary Outcome: Radiographic progression-free survival (rPFS).

• Result: 19% risk reduction (primary definition).

• rPFS with stricter PTEN criteria: 25% (95% threshold); 32% (100% threshold).

Conclusion: Adding capivasertib (Truqap) to abiraterone improves rPFS in PTEN-deficient mHSPC, with greater benefit seen with stricter PTEN loss definition; biomarker selection is essential for this targeted approach.

Limitations: Benefit increases with stricter PTEN deficiency definition; biomarker-dependent efficacy; requires immunohistochemistry testing; confirms importance of patient selection.

AMPLITUDE (Niraparib + Abiraterone in HRR-Mutated mCSPC)

Journal/Author: Nature Medicine (Attard G, et al., 2025)

Design: Phase 3 randomized, double-blind trial comparing niraparib plus abiraterone acetate and prednisone (AAP) versus placebo plus AAP.

Population: 696 patients with metastatic castration-sensitive prostate cancer and HRR gene alterations (56% BRCA1/2) across 32 countries; median age 68.

Primary Outcome: Radiographic progression-free survival (rPFS).

• BRCA subgroup: HR 0.52 (95% CI 0.37-0.72; p<0.0001).

• Intent-to-treat (ITT): HR 0.63 (95% CI 0.49-0.80; p=0.0001).

• Overall risk reduction: 37%.

Key Secondary Outcomes:

• Time to symptom worsening: Twice as long (34% vs. 16% with notable worsening).

• Overall survival trend: HR 0.79 favoring niraparib (immature data).

• Grade ≥3 adverse events: 75% vs. 59% (anemia 29%, hypertension 27%).

• Blood transfusions: 25% required.

Conclusion: Adding niraparib to abiraterone improves rPFS in mCSPC patients with HRR gene alterations, particularly those with BRCA mutations, representing the first positive PARP inhibitor trial in this setting.

Limitations: First positive PARPi trial in mCSPC; 16% received concurrent docetaxel; treatment-emergent deaths: 14 vs. 7; requires HRR testing at diagnosis; anemia burden significant; long-term OS benefit awaits confirmation.

⚗️ METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC)

TAX-327 (Docetaxel vs. Mitoxantrone)

Journal/Author: New England Journal of Medicine (Tannock IF, et al., 2004)

Design: Phase 3 randomized trial comparing docetaxel every 3 weeks, docetaxel weekly, and mitoxantrone.

Population: 1,006 men with metastatic castration-resistant prostate cancer (mCRPC).

Primary Outcome: Overall survival (docetaxel q3w).

• Result: 18.9 months vs. mitoxantrone 16.5 months (HR 0.76; p=0.009).

Key Secondary Outcomes:

• PSA response: 45% vs. 32% (p=0.001).

• Pain response: 35% vs. 22% (p=0.01).

• Quality of life improvement: 22% vs. 13% (p=0.009).

Conclusion: Docetaxel every 3 weeks improves survival, pain control, and quality of life compared to mitoxantrone, establishing it as the first-line standard of care in mCRPC.

Limitations: Mitoxantrone now obsolete comparator; neuropathy risk (30%) and febrile neutropenia (3%); pre-dates cabazitaxel, ARPIs, and PARP inhibitors; q3w regimen only (not q2w now common).

COU-AA-301 (Abiraterone Post-Docetaxel)

Journal/Author: Lancet (de Bono JS, et al., 2011)

Design: Phase 3 randomized trial comparing abiraterone acetate plus prednisone versus placebo in patients who had progressed after docetaxel.

Population: 1,195 men with mCRPC progressing after docetaxel chemotherapy.

Primary Outcome: Overall survival.

• Result: 15.8 months vs. 11.2 months (HR 0.74; p<0.0001).

Key Secondary Outcomes:

• Radiographic progression-free survival (rPFS): HR 0.66.

• PSA response: 38% vs. 10%.

• Time to PSA progression: 10.2 vs. 6.6 months.

• Pain palliation: 45% vs. 28%.

Conclusion: Abiraterone improves survival in post-docetaxel mCRPC, establishing AR-targeted therapy as a standard second-line option.

Limitations: Mineralocorticoid toxicities (hypertension 10%, hypokalemia 17%, edema 13%); requires prednisone; now largely replaced by first-line use in pre-chemotherapy setting.

COU-AA-302 (Abiraterone Pre-Chemotherapy)

Journal/Author: New England Journal of Medicine (Ryan CJ, et al., 2013)

Design: Phase 3 randomized trial comparing abiraterone acetate plus prednisone versus placebo in chemotherapy-naïve patients.

Population: 1,088 men with chemotherapy-naïve mCRPC.

Primary Outcome: Radiographic progression-free survival (rPFS) and overall survival (interim).

• rPFS: HR 0.53 (p<0.001).

• OS (interim): HR 0.75 (p=0.01).

Key Secondary Outcomes:

• Time to opiate use: HR 0.69.

• Time to ECOG performance status decline: HR 0.82.

• Time to chemotherapy initiation: HR 0.61.

Conclusion: Abiraterone improves radiographic PFS and overall survival in chemotherapy-naïve mCRPC, moving AR-targeted therapy to the first-line setting.

Limitations: Crossover allowed (44% of placebo crossed to abiraterone), diluting OS benefit; longer follow-up needed for definitive OS; mineralocorticoid toxicities still present.

AFFIRM (Enzalutamide Post-Docetaxel)

Journal/Author: New England Journal of Medicine (Scher HI, et al., 2012)

Design: Phase 3 randomized trial comparing enzalutamide versus placebo in patients who had progressed after docetaxel.

Population: 1,199 men with mCRPC after docetaxel chemotherapy.

Primary Outcome: Overall survival.

• Result: 18.4 months vs. 13.6 months (HR 0.63; p<0.001).

Key Secondary Outcomes:

• PSA response: 54% vs. 2%.

• Radiographic progression-free survival (rPFS): HR 0.40.

• Time to quality of life deterioration: HR 0.62.

• Pain palliation: Superior with enzalutamide.

Conclusion: Enzalutamide improves survival in post-docetaxel mCRPC, providing another effective AR-targeted therapy option.

Limitations: Fatigue (34%), hypertension (6.6%), seizure (0.6%—rare but serious); no head-to-head vs. abiraterone in this setting; crossover allowed (46% of placebo received enzalutamide post-trial).

PREVAIL (Enzalutamide Pre-Chemotherapy)

Journal/Author: New England Journal of Medicine (Ryan CJ, et al., 2014)

Design: Phase 3 randomized trial comparing enzalutamide versus placebo in chemotherapy-naïve patients.

Population: 1,717 men with chemotherapy-naïve mCRPC.

Primary Outcome: Overall survival and radiographic progression-free survival (rPFS).

• OS: HR 0.71 (p<0.001).

• rPFS: HR 0.19 (p<0.001).

Key Secondary Outcomes:

• Time to PSA progression: HR 0.17.

• Time to chemotherapy initiation: HR 0.35.

• Time to first skeletal event: HR 0.72.

Conclusion: Enzalutamide improves survival in chemotherapy-naïve mCRPC, establishing it as a first-line standard alongside abiraterone.

Limitations: Crossover allowed (40% of placebo received subsequent ARPI), potentially diluting OS; fatigue (36%), falls (5%), fractures (2%); very large effect size on rPFS (HR 0.19) questioned by some.

CARD (Cabazitaxel vs. Second ARPI)

Journal/Author: New England Journal of Medicine (de Wit R, et al., 2019)

Design: Phase 4 randomized, open-label trial comparing cabazitaxel versus a second AR-targeted therapy (abiraterone or enzalutamide) after prior docetaxel and ARPI treatment.

Population: 255 men with mCRPC progressing on docetaxel and within 12 months of ARPI therapy.

Primary Outcome: Imaging-based progression-free survival (rPFS).

• Result: HR 0.54 (95% CI 0.40-0.73; p<0.001).

Key Secondary Outcomes:

• Overall survival: HR 0.64 (95% CI 0.46-0.89; p=0.008).

• PSA response: 35.7% vs. 13.5%.

• Time to pain progression: HR 0.55.

• Symptomatic skeletal events: 21.3% vs. 33.5%.

Conclusion: Cabazitaxel improves outcomes compared to a second AR-targeted therapy in patients progressing on docetaxel and within 12 months of prior ARPI, supporting chemotherapy over sequential ARPI use in this setting.

Limitations: Open-label design; small sample size; specific population (post-docetaxel and post-ARPI within 12 months); not generalizable to all mCRPC; cabazitaxel toxicity (grade ≥3 neutropenia 56%).

VISION (177Lu-PSMA-617 in PSMA-Positive mCRPC)

Journal/Author: New England Journal of Medicine (Morris MJ, et al., 2021)

Design: Phase 3 randomized trial comparing 177Lu-PSMA-617 plus best supportive care versus best supportive care alone.

Population: 831 men with PSMA-positive mCRPC who had received prior ARPI and 1-2 taxane regimens.

Primary Outcome: Overall survival and radiographic progression-free survival (rPFS).

• OS: 15.3 vs. 11.3 months (HR 0.62; 95% CI 0.52-0.74; p<0.001).

• rPFS: 8.7 vs. 3.4 months (HR 0.40).

Key Secondary Outcomes:

• PSA response (≥50%): 46% vs. 1.5%.

• Time to first symptomatic skeletal event: HR 0.50.

• Quality of life: Delayed deterioration with 177Lu-PSMA-617.

Conclusion: 177Lu-PSMA-617 improves survival and delays symptomatic skeletal events in PSMA-positive mCRPC patients who have progressed on ARPI and taxane chemotherapy, establishing a new standard of care.

Limitations: Requires PSMA PET selection (PSMA-negative patients excluded); not all patients eligible; availability/cost; radiation safety precautions; dry mouth (39%), fatigue (43%), thrombocytopenia (8%).

TheraP (177Lu-PSMA-617 vs. Cabazitaxel)

Journal/Author: Lancet (Hofman MS, et al., 2021)

Design: Phase 2 randomized trial comparing 177Lu-PSMA-617 versus cabazitaxel.

Population: 200 men with mCRPC who had progressed after docetaxel, were PSMA-positive, and allowed FDG-discordant disease.

Primary Outcome: PSA response (≥50% reduction).

• Result: 66% vs. 37% (difference 29%; 95% CI 16-42; p<0.0001).

Key Secondary Outcomes:

• Progression-free survival: HR 0.64 (95% CI 0.46-0.88).

• Grade 3-4 adverse events: 33% vs. 53%.

• Quality of life: Better with 177Lu-PSMA-617.

Conclusion: 177Lu-PSMA-617 achieves higher PSA response rates and better quality of life with fewer grade 3-4 adverse events compared to cabazitaxel in PSMA-positive mCRPC, supporting its role as an alternative to chemotherapy.

Limitations: Phase II design; primary endpoint PSA response (surrogate); cross-over not allowed; requires both PSMA and FDG PET (complex selection); not powered for OS; smaller than VISION.

PROfound (Olaparib in HRR-Mutated mCRPC)

Journal/Author: New England Journal of Medicine (de Bono J, et al., 2020)

Design: Phase 3 randomized trial comparing olaparib versus enzalutamide or abiraterone in patients with HRR gene mutations.

Population: 387 men with mCRPC and HRR mutations (BRCA1/2, ATM, and others) progressing on prior ARPI.

Primary Outcome: Radiographic progression-free survival (rPFS) in Cohort A (BRCA1/2, ATM).

• Result: HR 0.34 (95% CI 0.25-0.47; p<0.001).

Key Secondary Outcomes:

• Overall survival (Cohort A): HR 0.64 (95% CI 0.43-0.97; p=0.02).

• Objective response rate: 33% vs. 2%.

• Time to pain progression: HR 0.44.

• Time to subsequent therapy: HR 0.36.

• OS (overall population): HR 0.67.

Conclusion: Olaparib improves outcomes compared to continued AR-targeted therapy in mCRPC patients with HRR gene mutations, particularly BRCA1/2, establishing PARP inhibition as standard of care in biomarker-selected populations.

Limitations: Requires genetic testing; only 20-25% of mCRPC patients have HRR mutations; no benefit in non-HRR patients; crossover allowed (66% of control crossed to olaparib); myelodysplasia/AML risk (rare but serious).

🧬 PARP INHIBITOR COMBINATIONS

TALAPRO-2 (Talazoparib + Enzalutamide)

Journal/Author: Lancet (Agarwal N, et al., 2023); Urology Times (Agarwal N, 2025)

Design: Phase 3 randomized, double-blind trial comparing talazoparib plus enzalutamide versus placebo plus enzalutamide.

Population: 805 patients with mCRPC (399 with HRR gene alterations in dedicated cohort).

Primary Outcome: Overall survival.

• BRCA2 subgroup: Median not reached vs. 28.5 months at 4 years.

• Overall cohort: 45.8 vs. 37.0 months (HR 0.79).

Key Secondary Outcomes:

• Radiographic progression-free survival: HR 0.63 (ITT).

• PFS2 (time to second progression): HR 0.77 (95% CI 0.64-0.91).

• Grade ≥3 adverse events: Relative risk 1.44 (95% CI 1.20-1.73).

• Quality of life: Reduced risk of deterioration.

Conclusion: Talazoparib plus enzalutamide is the first PARP inhibitor + ARPI combination to demonstrate a statistically significant and clinically meaningful overall survival benefit in mCRPC, supporting its use as a standard-of-care initial treatment option.

Limitations: Benefit driven primarily by BRCA2 subgroup; other HRR genes show less pronounced benefit; requires molecular testing; toxicity (anemia, fatigue) higher with combination.

PROpel (Olaparib + Abiraterone)

Journal/Author: NEJM Evidence (Clarke NW, et al., 2022)

Design: Phase 3 randomized trial comparing olaparib plus abiraterone versus placebo plus abiraterone.

Population: mCRPC patients (both HRR-selected and unselected populations).

Primary Outcome: Radiographic progression-free survival (rPFS).

• ITT: HR 0.61.

• HRRm: HR 0.50.

• BRCAm: HR 0.23.

Key Secondary Outcomes:

• OS (HRRm): HR 0.66.

• OS (BRCAm): HR 0.44.

• Grade ≥3 adverse events: Increased vs. control.

Conclusion: Olaparib plus abiraterone improves rPFS in mCRPC, with greatest benefit in BRCA-mutated patients; the role in unselected patients remains debated, reinforcing the importance of biomarker testing.

Limitations: Initial ITT analysis showed benefit, but subsequent OS analysis less robust; unselected population benefit remains controversial; requires biomarker testing for optimal patient selection.

MAGNITUDE (Niraparib + Abiraterone)

Journal/Author: Journal of Clinical Oncology (Chi KN, et al., 2023)

Design: Phase 3 randomized trial comparing niraparib plus abiraterone versus placebo plus abiraterone, with patients stratified by HRR status.

Population: mCRPC patients (HRR-mutated and non-HRR cohorts).

Primary Outcome: Radiographic progression-free survival (rPFS) in HRRm cohort.

• First analysis: HR 0.73.

• BRCAm subgroup: HR 0.53.

Key Secondary Outcomes:

• Time to symptomatic progression: HR 0.56.

• Overall survival (BRCAm): Favorable trend.

• No benefit in non-HRRm: HR 1.09 (futility stopping).

Conclusion: Niraparib plus abiraterone improves outcomes only in HRR-mutated mCRPC, with no benefit in non-HRR patients, confirming that PARP inhibitor combinations require biomarker selection.

Limitations: Futility stopping in non-HRRm arm confirms biomarker necessity; benefit driven by BRCA subgroup; study design included adaptive elements; anemia common.

⚡ IMMUNOTHERAPY TRIALS (PD-1 INHIBITORS)

KEYNOTE-641 (Pembrolizumab + Enzalutamide)

Journal/Author: Annals of Oncology (Graff JN, et al., 2025)

Design: Phase 3 randomized, double-blind trial comparing pembrolizumab plus enzalutamide versus placebo plus enzalutamide.

Population: 1,244 patients with chemotherapy-naïve mCRPC; randomized 1:1; median follow-up 27.6 months.

Primary Outcome: Overall survival and radiographic progression-free survival (rPFS).

• OS: 24.7 vs. 27.3 months (HR 1.04; 95% CI 0.88-1.22; P=0.66)—NOT MET.

• rPFS: 10.4 vs. 9.0 months (HR 0.98; 95% CI 0.84-1.14; P=0.41)—NOT MET.

Key Secondary Outcomes:

• Grade ≥3 treatment-related adverse events: 31.2% vs. 10.8%.

• Treatment discontinuation: 11.5% vs. 3.4%.

• Futility boundary crossed: Trial terminated early.

Conclusion: Adding pembrolizumab to enzalutamide does not improve efficacy in chemotherapy-naïve mCRPC and increases toxicity, confirming that unselected PD-1 inhibition has no role in this population.

Limitations: Study stopped for futility; increased toxicity with no benefit; largest negative IO trial in mCRPC; enzalutamide remains standard alone.

KEYNOTE-921 (Pembrolizumab + Docetaxel)

Journal/Author: Journal of Clinical Oncology (Petrylak DP, et al., 2025)

Design: Phase 3 randomized, double-blind trial comparing pembrolizumab plus docetaxel versus placebo plus docetaxel.

Population: 1,030 patients with mCRPC progressing after ARPI; 1:1 randomization.

Primary Outcome: Overall survival and radiographic progression-free survival (rPFS).

• rPFS: 8.6 vs. 8.3 months (HR 0.85; 95% CI 0.71-1.01; P=0.03—prespecified significance boundary not met).

• OS: 19.6 vs. 19.0 months (HR 0.92; 95% CI 0.78-1.09; P=0.17)—NEITHER MET.

Key Secondary Outcomes:

• Grade ≥3 treatment-related adverse events: 43.2% vs. 36.6%.

• Pneumonitis: 7.0% vs. 3.1%.

• Treatment-related deaths: 2 vs. 7.

• PSA response rate: Secondary endpoint not met.

Conclusion: Pembrolizumab adds no benefit to docetaxel in mCRPC patients progressing after ARPI, reinforcing the lack of efficacy for PD-1 inhibition in unselected prostate cancer.

Limitations: Primary endpoints not met; numerically small rPFS benefit (0.3 months) not significant; OS no difference; docetaxel remains standard; no role for unselected pembrolizumab.

KEYNOTE-991 (Pembrolizumab + Enzalutamide + ADT in mHSPC)

Journal/Author: Annals of Oncology (Gratzke C, et al., 2025)

Design: Phase 3 randomized, double-blind trial comparing pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT.

Population: 1,251 patients with mHSPC (NHA-naïve); primary completion date October 31, 2022.

Primary Outcome: Radiographic progression-free survival (rPFS) and overall survival (OS).

• rPFS: HR 1.20 (95% CI 0.96-1.49; P=0.9467)—NOT MET.

• OS: HR 1.16 (95% CI 0.88-1.53)—NOT MET.

Key Secondary Outcomes:

• Grade ≥3 adverse events: 61.9% vs. 38.1%.

• Serious adverse events: 40.3% vs. 23.2%.

• Rash (any grade): 25.1% vs. 9.3%.

Conclusion: Pembrolizumab fails to improve outcomes in mHSPC when added to enzalutamide and ADT, extending the negative findings from mCRPC to the hormone-sensitive setting.

Limitations: Study stopped for futility; first-line mHSPC setting also negative; higher toxicity without efficacy; rash identified as safety signal.

KEYLYNK-010 (Pembrolizumab + Olaparib)

Journal/Author: ClinicalTrials.gov (NCT03834519)

Design: Phase 3 randomized, open-label trial comparing pembrolizumab plus olaparib versus abiraterone or enzalutamide.

Population: mCRPC patients who failed prior ARPI and chemotherapy.

Primary Outcome: Overall survival and radiographic progression-free survival (rPFS).

• Status: Completed September 2022; negative.

• DMC oversight removed suggesting futility.

Conclusion: The combination of pembrolizumab and olaparib does not improve outcomes over AR-targeted therapy in mCRPC, demonstrating that even combination immunotherapy fails in unselected populations.

Limitations: Negative trial; pembro + olaparib failed to improve outcomes over NHA in post-ARPI/post-chemo setting; DMC oversight removed suggesting futility.

🧬 MSI-H / dMMR PROSTATE CANCER (Pembrolizumab)

KEYNOTE-158 Pooled Analysis (FDA Full Approval)

Journal/Author: Urology Times (FDA announcement, 2023)

Design: Pooled analysis of 3 phase 2 trials (KEYNOTE-158, KEYNOTE-164, KEYNOTE-051) leading to full FDA approval.

Population: 504 adult and pediatric patients with more than 30 cancer types, including prostate cancer; MSI-H/dMMR solid tumors progressing after prior treatment.

Primary Outcome: Objective response rate (ORR).

• Result: 33.3% (95% CI 29.2%-37.6%).

• Complete response rate: 10.3%.

• Partial response rate: 23.0%.

Key Secondary Outcomes:

• Median duration of response (DOR): 63.2 months (range 1.9+ to 63.9+).

• 12-month DOR rate: 77%.

• 36-month DOR rate: 39%.

• Non-colorectal cancer ORR: 33% (95% CI 28%-38%).

Conclusion: Pembrolizumab achieves durable responses in MSI-H/dMMR tumors across histologies, including prostate cancer, supporting routine testing for this biomarker and its use as a standard therapy in this rare but highly responsive subset.

Limitations: Tumor-agnostic design with few prostate cancer patients; conversion from accelerated to full approval; requires MSI-H/dMMR testing; immune-mediated adverse events require monitoring (pneumonitis, colitis, hepatitis, endocrinopathies).

Altomare et al. (Biomarker-Selected mCRPC)

Journal/Author: The Oncologist (Altomare NJ, et al., 2025)

Design: Single-center retrospective study.

Population: 18 patients with mCRPC treated with pembrolizumab for a biomarker-driven indication (MSI-H, TMB-H, MMRd, or CDK12 alteration).

Primary Outcome: PSA50 response rate.

• Result: 38.9% (7/18 patients).

Key Secondary Outcomes:

• All PSA responders had MSI-H.

• 60% of MSI-H/TMB-H co-occurring patients responded.

• Median time on therapy (MSI-H): 11.5 months.

• Durable responses: One patient with MSI-H/TMB-H remained on pembrolizumab for 47 months with 100% PSA decline.

Conclusion: In biomarker-selected mCRPC, all PSA responses to pembrolizumab occurred in patients with MSI-H, reinforcing that this biomarker, rather than TMB alone, predicts immunotherapy benefit.

Limitations: Small, retrospective, single-center; heterogeneity in prior treatments and molecular testing platforms; cannot determine independent contribution of TMB vs. MSI-H as they often co-occur.

Lambert et al. (MSI-H mCRPC Case Series)

Journal/Author: Clinical Genitourinary Cancer (Lambert N, et al., 2025)

Design: Institutional case series.

Population: 13 patients with MSI-H metastatic prostate cancer (12 mCRPC, 1 mCSPC) treated with pembrolizumab between 2019-2024; heavily pre-treated (mean 2.7 prior lines).

Primary Outcome: PSA50 response rate (mCRPC).

• Result: 75% (9/12 patients).

Key Secondary Outcomes:

• Complete biochemical response: 58.3% (7/12) with undetectable PSA.

• Objective response rate (RECIST/PCWG3): 57.1% (2 complete responses, 2 partial responses).

• Median progression-free survival/overall survival: Not reached at median 14.4 months follow-up.

• HRR gene co-mutation: 6/7 complete responders had HRR mutation.

Conclusion: MSI-H prostate cancer demonstrates high response rates to pembrolizumab, with over half of patients achieving undetectable PSA, confirming the exceptional sensitivity of this molecular subtype to immunotherapy.

Limitations: Small series; retrospective; single-institution; median follow-up relatively short (14.4 months); mCSPC patient reported separately (n=1).

📊 SUMMARY OF KEY THERAPEUTIC SHIFTS

LANDMARK BLADDER CANCER TRIALS

🔬 MRI-BASED DIAGNOSTIC PATHWAYS: REPLACING TURBT FOR STAGING

BladderPath Trial (MRI-First vs. Standard TURBT Pathway)

Journal/Author: ESMO Congress 2025 (James N, Bryan R, et al.); Institute of Cancer Research

Design: Multistage, multicenter, randomized controlled trial conducted across 15 sites in the UK. The study compared an imaging-first diagnostic pathway using multiparametric MRI (mpMRI) versus the standard pathway of transurethral resection of bladder tumor (TURBT) for patients with suspected muscle-invasive bladder cancer (MIBC).

Population: 143 participants newly presenting with a bladder mass following initial exploratory diagnosis. Patients were randomized to either the standard pathway (waiting list for TURBT) or the experimental pathway (multiparametric MRI prior to TURBT).

Primary Outcome: Time from diagnosis to definitive treatment.

• Result: The MRI-first pathway led to significantly fewer delays in diagnosis (42% among those receiving MRI first vs. 54% on standard pathway).

Key Secondary Outcomes:

• Bladder cancer-specific deaths: 10% on MRI pathway vs. 18% on standard pathway.

• Median time reduction: Approximately 45-day reduction in time to treatment initiation .

• Cost-effectiveness: MRI is considerably cheaper than TURBT; the new pathway saves surgical theatre space and hospital bed days.

• Procedure avoidance: Pre-surgery imaging allows some patients to either avoid surgery altogether or have a more limited procedure.

Take-home Message: Adding an MRI pre-biopsy not only cuts the time to receive treatment but also reduces bladder cancer deaths. This simple change to the patient pathway saves lives and should be adopted immediately . The bladder cancer diagnostic pathway had remained essentially unchanged for more than 30 years—these results confirm that new approaches can make a significant difference .

Limitations: The trial had a relatively short follow-up period (14 months) for oncologic outcomes. The findings must be interpreted with caution given the restrictive inclusion of patients with suspected muscle-invasive disease only (excluding NMIBC) . Implementation variability and access disparities to high-quality MRI remain challenges .

BladParadigm Study (mpMRI vs. TURBT for Local Staging) – Ongoing

Journal/Author: BMJ Open (van Koeverden SW, et al., 2025); NIH PMC

Design: Two-arm, multicenter, non-inferiority randomized controlled trial conducted in the Netherlands. The study hypothesizes that substituting TURBT with a new diagnostic pathway including mpMRI and same-day outpatient bladder biopsy will improve outcomes.

Population: 360 patients (planned) with clinically suspected MIBC without evidence of metastases, randomized 1:1 to either:

• Standard arm: TURBT according to EAU guidelines

• Intervention arm: 3-Tesla mpMRI with same-day outpatient bladder biopsy (using VI-RADS standardized reporting)

Primary Outcome: 2-year progression-free survival.

Key Secondary Outcomes:

• Time to definitive treatment

• Quality of life (EuroQol 5D-5L)

• Healthcare costs and cost-effectiveness

Rationale: The trial is based on the hypothesis that TURBT may be partly responsible for tumor cell spread, as evidenced by studies demonstrating circulating tumor cells (CTCs) in blood following resection. Furthermore, TURBT contributes to significant delays to definitive therapy .

Take-home Message: This is one of the first large, multicenter RCTs comparing an mpMRI-based diagnostic pathway to the current standard of care, conducted in both academic and community hospitals. Results will determine whether an mpMRI-based approach can safely replace TURBT in terms of both effectiveness and costs .

Strengths: Standardized VI-RADS protocol for acquisition and reporting; double-reading of all scans to ensure robust diagnosis; central review of surgical specimens to assess diagnostic validity of mpMRI .

Limitations: Inclusion is based on cystoscopic assessment, which is subjective and may vary between clinicians.

VI-RADS Validation and Biparametric MRI Trials

Context: The Vesical Imaging-Reporting and Data System (VI-RADS) was developed to standardize mpMRI acquisition and interpretation, improving inter-reader agreement and enhancing reliability in clinical practice. Meta-analyses have reported high sensitivity (83–90%) and specificity (88–90%) for mpMRI in assessing detrusor muscle invasion .

PHOTO Trial (PDD vs. White Light Cystoscopy)

• Journal/Author: Cited in Cureus review

• Key Finding: Photodynamic diagnosis (PDD) significantly improves tumor detection but did not significantly reduce long-term recurrence rates compared to white light cystoscopy (HR 0.94; 95% CI 0.69-1.28; P=0.70). Three-year recurrence-free survival was 57.8% for PDD vs. 61.6% for white light. No evidence of cost-effectiveness or quality-of-life benefit was found.

ERBT Meta-Analysis (En Bloc Resection)

• Key Finding: En bloc resection of bladder tumor (ERBT) reduced the risk of bladder perforation (RR 0.13; 95% CI 0.05-0.34) and improved detrusor muscle presence in specimens (RR 1.31; 95% CI 1.19-1.43), but did not significantly lower recurrence rates at 12 and 24 months .

metricMRI Trial (Biparametric vs. Multiparametric MRI) – Ongoing

• Journal/Author: ClinicalTrials.gov (NCT05783271); Assiut University

• Design: Prospective study evaluating the validity of non-contrast biparametric MRI (bp-MRI) compared to mp-MRI using VI-RADS scoring.

• Population: 58 patients with suspected bladder cancer.

• Primary Outcome: Diagnostic accuracy of bp-MRI vs. mp-MRI for detecting muscle invasion.

• Rationale: To avoid contrast material-related complications and determine whether contrast is essential for local staging.

• Status: Recruiting (estimated completion December 2026).

Take-home Message: While TURBT enhancements improve surgical quality, mpMRI offers more reliable non-invasive staging for pre-treatment decision-making. A prospective validation study reported sensitivity of 91.9%, specificity of 91.1%, and AUC of 0.94 for discriminating NMIBC from MIBC, with strong inter-reader agreement (k=0.81) .

🔬 URINARY BIOMARKERS FOR SURVEILLANCE (REDUCING CYSTOSCOPY)

DaBlaCa-15 Trial (Xpert Bladder Cancer Monitor for Follow-up)

Journal/Author: European Urology (Dreyer T, et al., 2025); PubMed

Design: Randomized, controlled, non-inferiority trial evaluating the impact of alternating the Xpert Bladder Cancer Monitor (XBCM) urinary biomarker test with cystoscopy for follow-up of high-grade NMIBC.

Population: Patients with previous high-grade NMIBC and no recurrence confirmed at inclusion cystoscopy. 190 patients in the intervention arm, 187 in the control arm.

Intervention: Two-year follow-up with:

• Control arm: Cystoscopy and urinary cytology every 4 months.

• Intervention arm: XBCM testing and urinary cytology every 4 months, plus cystoscopy at months 12 and 24. Any positive XBCM or suspicious cytology triggered cystoscopy within 14 days.

Primary Outcome: Risk of recurrence-free survival (high-grade NMIBC, MIBC, or metastatic disease).

• Result: Non-inferiority demonstrated—risk difference 0.08% (95% CI -7.2% to 7.4%).

• Recurrence at 24 months: 12% in intervention arm vs. 11% in control arm.

Key Secondary Outcomes:

• Cystoscopy reduction: 455 cystoscopies in intervention arm vs. 1029 in control arm—a 55% reduction.

• Test performance (XBCM): Sensitivity 91%, Specificity 65%, NPV 99%, PPV 16%.

• Cytology performance: Sensitivity 9%, Specificity 97%.

• Lead time: Among patients with high-grade recurrence, 13 had positive XBCM prior to histological confirmation, with median lead time of 8.3 months.

• Missed cancers: Two pTa high-grade recurrences in the intervention arm occurred in patients with negative XBCM throughout; both were detected at prescheduled cystoscopies.

Take-home Message: Alternating cystoscopy with XBCM halves the number of follow-up cystoscopies for high-grade NMIBC without affecting detection of recurrence. The test demonstrates 91% sensitivity and 99% negative predictive value, with the ability to predict recurrence a median of 8 months before visible disease . These results have the potential to significantly influence future clinical guidelines on NMIBC management .

Limitations: Recurrence rate was lower than expected across both groups, possibly reflecting improvements in treatment and imaging. Results are specific to the XBCM test and do not necessarily apply to other urinary biomarkers. Long-term oncological safety requires validation over longer follow-up .

🔬 EMERGING LIQUID BIOPSY TECHNOLOGIES

Galeas Bladder Urine Test Trials

Journal/Author: Birmingham Health Partners (Nonacus/University of Birmingham, 2025)

Design: Two West Midlands-based trials assessing a novel at-home urine test for monitoring bladder cancer recurrence, using Nonacus’ highly-sensitive liquid biopsy technology.

Technology: The Galeas Bladder test was developed in conjunction with a panel of biomarkers developed by researchers from the University of Birmingham’s Bladder Cancer Research Centre. A previous Cancer Research UK-funded study has already shown that it can accurately and consistently detect the presence of bladder cancer from a urine sample .

Context: Bladder cancer can often be diagnosed late and has a high level of recurrence—which can lead to poor outcomes for patients. Bladder cancer has been neglected in terms of new research in the past .

Take-home Message: These trials represent the culmination of eight years of collaborative research and development, with the potential to help the millions of patients at higher risk of bladder cancer worldwide . The technology has the potential to transform the lives of patients through non-invasive testing .

UCA1 Biomarker Study (Johns Hopkins)

Journal/Author: Urology (Higgins M, Kates M, et al., 2025); Johns Hopkins Medicine

Design: Prospective study investigating whether UCA1, an RNA molecule elevated in bladder cancer, could accurately identify high-grade bladder cancer in urine.

Population: 50 patients with bladder cancer.

Methods: RNA in situ hybridization (RISH) was used to detect UCA1 in urine samples, compared to standard cytology.

Key Findings:

• RISH detection of high-grade bladder cancer: 67%

• Cytology detection: 34%

• Combined testing (RISH + cytology): 78% detection rate

Take-home Message: UCA1 is showing promise as a new way to identify dangerous bladder cancers in a non-invasive way. It could also help monitor patients over time and help detect shifts from low to high-grade disease sooner .

Limitations: Further research is needed to confirm these findings in larger cohorts.

📊 SUMMARY OF KEY THERAPEUTIC SHIFTS IN BLADDER CANCER DIAGNOSIS

🔬 NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)

Foundational BCG Trials (Lamm et al.)

Journal/Author: Journal of Urology (Lamm DL, et al., 1980); Urology (Lamm DL, 1995); Journal of Urology (Lamm DL, et al., 2000)

Design: Series of randomized trials establishing the efficacy of BCG and defining optimal maintenance schedules.

Population: Patients with high-risk NMIBC, including carcinoma in situ (CIS), Ta, and T1 tumors.

Key Findings:

• BCG significantly reduces recurrence and progression compared to TURBT alone or intravesical chemotherapy.

• Maintenance BCG (3-week instillations at 3, 6, 12, 18, 24, 30, and 36 months) improves long-term outcomes compared to induction alone.

• Long-term follow-up confirmed sustained reduction in disease progression and need for cystectomy.

Conclusion: BCG with maintenance therapy became the standard of care for high-risk NMIBC, reducing recurrence rates by approximately 40% and progression by 27% compared to TURBT alone.

Limitations: Significant toxicity including cystitis, hematuria, and rarely systemic BCGosis; optimal duration of maintenance remains debated; up to 40% of patients eventually fail BCG and require alternative strategies.

ENVISION Trial (UGN-102 for Low-Grade Intermediate-Risk NMIBC)

Journal/Author: The Journal of Urology (Prasad SM, et al., 2025); CancerNetwork

Design: Open-label, single-arm, phase 3 trial evaluating UGN-102, an intravesical mitomycin-containing reverse-thermal gel, as primary chemoablative therapy.

Population: 240 patients with recurrent, low-grade, intermediate-risk NMIBC. Most tumors were multifocal (83%), with a mean size of 2.5 cm. Patients had at least one prior instance of low-grade NMIBC requiring TURBT. Nearly all patients (95%) completed 6 weekly intravesical instillations.

Primary Outcome: Complete response (CR) rate at 3 months.

• Result: 79.6% (191/240 patients; 95% CI, 73.9%-84.5%).

Key Secondary Outcomes:

• Duration of response (DOR) at 12 months: 82.3% (95% CI, 75.9%-87.1%).

• DOR at 15 and 18 months following 3-month CR: Both 80.9% (95% CI, 73.9%-86.2%).

• Disease-free survival (DFS) at 15 months: 76% (95% CI, 69.7%-81.1%).

• Median DOR: Not estimable at median follow-up of 13.9 months.

Conclusion: UGN-102 demonstrates clinically meaningful complete response rates with remarkable durability in patients with low-grade, intermediate-risk NMIBC, representing a promising non-surgical alternative to transurethral resection.

Limitations: Single-arm design without randomized comparator; FDA’s Oncologic Drugs Advisory Committee expressed concerns about data robustness; requires confirmation in randomized settings.

SunRISe-1 (TAR-200 in BCG-Unresponsive High-Risk NMIBC)

Journal/Author: Targeted Oncology (Jacob J, et al., 2025 AUA Meeting)

Design: Phase 2b study evaluating TAR-200, a novel intravesical drug-releasing system providing sustained delivery of gemcitabine.

Population: Patients with BCG-unresponsive, high-risk NMIBC with carcinoma in situ (CIS) with or without papillary disease. Cohort 2 (n=85) received TAR-200 monotherapy. Median age 71 years; 80% male; median prior BCG doses: 12 (range 7-42).

Primary Outcome: Overall complete response rate.

• Result: 82.4% (95% CI, 72.6%-89.8%).

Key Secondary Outcomes:

• 12-month CR rate: 45.9%.

• Kaplan-Meier estimated CR rates: 52.4% at 12 months, 44.7% at 24 months.

• Median time to onset of CR: 2.8 months (range, 2.1-8.3).

• Patients achieving CR within first 3 months: 95.7% (67/70).

Conclusion: TAR-200 achieves the highest single-agent complete response rate reported to date in BCG-unresponsive high-risk NMIBC with CIS, offering a promising bladder-sparing option.

Limitations: Single-arm phase 2 design; no comparator arm; relatively short follow-up for durability assessment.

LEGEND Trial (Detalimogene in BCG-Unresponsive NMIBC)

Journal/Author: Global Oncology Academy (2025)

Design: Single-arm Phase 2 pivotal trial of intravesical detalimogene, a gene therapy delivering interferon-α via adenoviral vector.

Population: BCG-unresponsive NMIBC with carcinoma in situ (CIS). Pivotal enrollment: 125 patients overall.

Primary Outcome: Complete response rate at 6 months.

• Result: 62% (23/37 evaluable patients).

Key Secondary Outcomes:

• Safety: Favorable tolerability profile; 42% treatment-related AEs; dose interruptions 1.6%; discontinuations 0.8%; few Grade 3 events; no Grade 4-5 toxicities.

• Local delivery: Limits systemic exposure and permits repeat dosing.

Conclusion: Detalimogene offers a promising bladder-sparing alternative to immediate cystectomy for BCG-unresponsive CIS, with robust early tumor clearance.

Limitations: Single-arm design; confirmatory trials and regulatory review pending.

ABC Trial (Avelumab + BCG in BCG-Unresponsive NMIBC)

Journal/Author: Journal of Urology (Cookson M, et al., 2021 – AUA Late-Breaking Abstract); AUA Journals (NCT03892642)

Design: Open-label Phase Ib trial evaluating the safety and tolerability of a novel intense weekly dosing regimen of avelumab (anti-PD-L1) in combination with BCG induction therapy for patients with BCG-unresponsive NMIBC.

Population: 18 patients (14 male, 4 female; median age 69.9 years) with a history of NMIBC and prior BCG therapy. Majority (9 patients) had T1 stage tumors, 5 had Ta, and 4 had Tis.

Treatment Protocol:

• Following tumor resection, patients underwent a 6-week BCG induction with weekly avelumab infusion (10 mg/kg IV).

• This was followed by BCG maintenance therapy with weekly avelumab for 12 months.

• Between BCG treatments, bi-weekly avelumab infusion (10 mg/kg IV) was given.

Primary Outcome: Completion of a full induction course (5 out of 6 treatments with BCG and avelumab) within 8 weeks of treatment initiation.

• Result: 15/18 (83%) patients completed induction therapy; 16 received at least 5 BCG treatments and 15 received at least 5 avelumab treatments—exceeding the 60% anticipated completion rate.

Key Secondary Outcomes:

• 3-month cystoscopy: 13/15 (87%) patients remained on treatment; 10 without evidence of cancer; 3 with persistent disease (2 CIS, 1 Ta).

• Safety: No drug-attributable grade 4 or 5 adverse events observed.

• Grade 3 adverse events: 2 (11%) patients had probable drug-related grade 3 events (infusion-related reaction from avelumab, and sepsis from BCG).

Conclusion: In BCG-unresponsive NMIBC patients, induction therapy with combined BCG and avelumab was safe and well tolerated. This study supports continued efforts to evaluate the optimal dosing regimen to synergize BCG and immunotherapy.

Limitations: Phase Ib design with small sample size (n=18); single-arm study without comparator; primarily safety-focused with efficacy as a secondary endpoint; longer follow-up needed for durability assessment.

Source of Funding: EMD Serono, Inc., USA (an affiliate of Merck KGaA, Darmstadt, Germany) as part of an alliance between Merck KGaA and Pfizer.

CREST Study (Sasanlimab + BCG in BCG-Naive High-Risk NMIBC)

Journal/Author: Nature Medicine (Shore ND, et al., 2025); GU Oncology Now (Brown G, 2025)

Design: Phase 3 randomized, open-label trial across 14 countries. Patients randomized 1:1:1 to sasanlimab (anti-PD-1) plus BCG induction and maintenance (Arm A), sasanlimab plus BCG induction alone (Arm B), or BCG induction and maintenance alone (Arm C).

Population: 1,055 patients with BCG-naïve, high-risk NMIBC (T1, high-grade Ta, or CIS). Most patients had T1 disease (>50%) or CIS (~25%).

Primary Outcome: Event-free survival (EFS).

• Result: Addition of sasanlimab to BCG induction and maintenance reduced risk of EFS event by 32% (stratified HR, 0.68; 95% CI, 0.49-0.94; 1-sided P = 0.0095).

• 36-month EFS rates: 82.1% (sasanlimab + BCG) vs. 74.8% (BCG alone).

Key Secondary Outcomes:

• Patients with CIS: 36-month complete response probability 92% vs. 84.7%.

• Arm B vs. Arm C: No significant EFS difference with sasanlimab plus BCG induction alone, confirming maintenance is essential.

• Overall survival (immature): No significant difference; median follow-up 40.9 months with only 8.6% deaths.

• Safety profile: Consistent with known immune-related adverse events; no unexpected signals.

Conclusion: This first trial demonstrating statistically significant prolongation of event-free survival with an immunotherapy combination in BCG-naïve high-risk NMIBC represents a potential new standard of care.

Limitations: OS data immature; optimal patient selection requires further refinement; cost-effectiveness considerations.

POTOMAC Trial (Durvalumab + BCG)

Journal/Author: NIH PMC Table NCT03528694; GU Oncology Now

Design: Phase 3 randomized controlled trial comparing durvalumab (anti-PD-L1) plus BCG induction and maintenance versus durvalumab plus BCG induction only versus BCG standard-of-care therapy.

Population: BCG-naïve high-risk NMIBC patients.

Primary Outcome: Disease-free survival.

Status: The trial has recently read out positively, although full results have not yet been publicly disclosed.

Conclusion: Together with CREST, POTOMAC signals a paradigm shift toward IO-BCG combinations in high-risk NMIBC.

KEYNOTE-676 (Pembrolizumab + BCG)

Journal/Author: NIH PMC Table NCT03711032; GU Oncology Now

Design: Phase 3 randomized controlled trial comparing pembrolizumab plus BCG versus BCG monotherapy.

Population: Two cohorts: (A) high-risk NMIBC recurrent after adequate BCG induction; (B) BCG-naïve high-risk NMIBC.

Primary Outcomes: Complete response rate and event-free survival.

Status: Estimated completion October 2028; results awaited.

🔬 MUSCLE-INVASIVE BLADDER CANCER (MIBC) – NEOADJUVANT CHEMOTHERAPY

ABC Meta-analysis Collaboration (Neoadjuvant Chemotherapy – 2005 Update)

Journal/Author: European Urology (Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, 2005); ScienceDirect

Design: Systematic review and meta-analysis of updated individual patient data from all eligible randomized controlled trials comparing neoadjuvant chemotherapy plus local treatment (cystectomy or radiotherapy) versus the same local treatment alone.

Population: 3,005 patients from 11 randomized controlled trials, comprising 98% of all patients from known eligible randomized controlled trials. All trials used platinum either as a single agent or in combination with other drugs.

Primary Outcome: Overall survival.

• Result: Significant survival benefit associated with platinum-based combination chemotherapy (HR = 0.86, 95% CI 0.77–0.95, p = 0.003).

• Absolute improvement: 5% improvement in survival at 5 years (from 45% to 50%).

Key Secondary Outcomes:

• Disease-free survival: HR = 0.78 (95% CI 0.71–0.86, p < 0.0001), equivalent to a 9% absolute improvement at 5 years.

• Interaction analysis: Benefit most clear for trials using platinum-based combination chemotherapy (p for interaction = 0.029).

• Nordic trials combined analysis: ARR 8% overall; T3-subgroup ARR 11% (HR 0.69) with 5-year OS 48% vs. 37%.

Conclusion: This meta-analysis provides the best available evidence in support of neoadjuvant platinum-based combination chemotherapy, which continues to show a clear and modest benefit for survival and disease-free survival. It remains the treatment against which all new treatments for invasive bladder cancer should be judged.

Limitations: Relatively modest absolute benefit (5%); heterogeneity across trials in chemotherapy regimens; relatively low age of study populations (median age in 60s); applicability to modern radiotherapy techniques not directly assessed.

ABC Meta-analysis Collaboration (Neoadjuvant Chemotherapy – 2003 Original)

Journal/Author: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2003)

Design: Original individual patient data meta-analysis based on 10 randomized controlled trials (including one unpublished).

Population: 2,688 patients, comprising 88% of patients from all known eligible randomized controlled trials.

Primary Outcome: Overall survival.

• Result: 9% relative reduction in the risk of death on chemotherapy compared to control.

• For platinum-based combination chemotherapy trials: 13% relative reduction in risk of death (p = 0.016), equivalent to a 5% absolute survival benefit at 5 years.

Significance: This landmark analysis established neoadjuvant platinum-based combination chemotherapy as the standard of care for muscle-invasive bladder cancer.

Nordic Cystectomy Trials 1 & 2 (Combined Analysis)

Journal/Author: European Urology (Sherif A, et al., 2004); cited in SciELO

Design: Combined analysis of two Nordic trials (Nordic Cystectomy Trial 1 and 2) evaluating neoadjuvant cisplatin-based combination chemotherapy.

Population: Patients with muscle-invasive bladder cancer undergoing cystectomy.

Primary Outcome: Overall survival.

• Result: Absolute risk reduction (ARR) of 8% for the trial as a whole.

• T3-subgroup (UICC 1982): ARR of 11%; HR 0.69.

• 5-year OS (T3): 48% (chemotherapy) vs. 37% (control).

• T2-subgroup: HR 0.85 (not statistically significant).

Significance: The trials were comparatively large and clinically homogeneous, conducted within the same recruitment areas and within a similar biological domain with cystectomy as baseline treatment. This analysis contributed substantially to the ABC meta-analysis findings.

SWOG 8710 (Neoadjuvant MVAC + Cystectomy vs. Cystectomy Alone)

Journal/Author: New England Journal of Medicine (Grossman HB, et al., 2003)

Design: Phase III randomized trial comparing neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) followed by radical cystectomy versus cystectomy alone.

Population: Patients with locally advanced bladder cancer (muscle-invasive disease).

Primary Outcome: Overall survival.

• Result: Neoadjuvant MVAC significantly improved overall survival compared to cystectomy alone.

• Median survival: 77 months (MVAC + cystectomy) vs. 46 months (cystectomy alone).

Key Secondary Outcomes:

• Pathological complete response (pCR) rate: 38% in neoadjuvant arm.

• Perioperative morbidity/mortality: No significant increase with neoadjuvant therapy.

Conclusion: This landmark trial confirmed the survival benefit of neoadjuvant cisplatin-based combination chemotherapy, demonstrating that chemotherapy before cystectomy improves survival without compromising surgical safety.

Limitations: MVAC regimen associated with significant toxicity (febrile neutropenia, mucositis); largely replaced by gemcitabine-cisplatin in contemporary practice.

BA06 30894 (International Neoadjuvant Chemotherapy Trial – CMV)

Journal/Author: Journal of Clinical Oncology (Griffiths G, et al., 2011)

Design: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine (CMV) chemotherapy.

Population: Patients with muscle-invasive bladder cancer scheduled for radical cystectomy or radiotherapy.

Primary Outcome: Long-term overall survival.

• Result: Neoadjuvant CMV significantly improved overall survival compared to no chemotherapy.

Conclusion: This trial confirmed the survival benefit of neoadjuvant cisplatin-based combination chemotherapy, demonstrating that benefits persist with extended follow-up.

Limitations: CMV regimen has been largely replaced by gemcitabine-cisplatin; applicability to modern radiotherapy techniques not directly assessed.

Herchenhorn et al. (Neoadjuvant Gemcitabine + Cisplatin Phase II)

Journal/Author: International Brazilian Journal of Urology (Herchenhorn D, et al., 2007); discussed in SciELO

Design: Phase II trial evaluating neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma.

Population: Patients with resectable bladder cancer; ages ranging from 18-70 with a median age of 63.

Significance: By utilizing gemcitabine, the tolerability of neoadjuvant therapy increases, potentially enabling patients of higher age to be treated. The combination of gemcitabine and cisplatin has since become the most commonly used neoadjuvant regimen due to its favorable toxicity profile compared to MVAC.

VESPER (Perioperative ddMVAC vs. GC)

Journal/Author: Lancet Oncology (Pfister C, et al., 2021); ASCO Daily News

Design: Phase 3 randomized trial comparing 6 cycles of dose-dense MVAC (ddMVAC) versus 4 cycles of gemcitabine-cisplatin (GC) in the perioperative setting.

Population: 500 patients with MIBC scheduled for cystectomy.

Primary Outcome: 3-year progression-free survival (PFS) in intent-to-treat population.

• Result: 64% (ddMVAC) vs. 56% (GC); P = 0.066 – NOT STATISTICALLY SIGNIFICANT.

Key Secondary Outcomes:

• Neoadjuvant pCR rate (RC-evaluable): 42% (ddMVAC) vs. 36% (GC).

• 5-year overall survival: 66% vs. 57%; HR 0.71 (favoring ddMVAC).

• Treatment completion: Only 60% completed all 6 cycles of ddMVAC vs. 84% of GC arm.

Conclusion: Although ddMVAC showed higher pCR rates and improved OS in secondary analyses, the primary endpoint was not met. GC remains a standard neoadjuvant regimen with better tolerability and completion rates.

Limitations: Trial design used 6 cycles of ddMVAC, which is not standard; higher pCR rates may reflect RC-evaluable rather than ITT analysis.

🔬 MUSCLE-INVASIVE BLADDER CANCER (MIBC) – ADJUVANT CHEMOTHERAPY

ABC Meta-analysis Collaboration (Adjuvant Chemotherapy – 2005)

Journal/Author: European Urology (Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, 2005)

Design: Systematic review and meta-analysis of individual patient data from all available randomized controlled trials evaluating adjuvant chemotherapy in invasive bladder cancer.

Population: Patients with muscle-invasive bladder cancer who had undergone radical cystectomy.

Primary Outcome: Overall survival.

• Result: Demonstrated a benefit for adjuvant platinum-based combination chemotherapy, though the evidence base was more limited than for neoadjuvant therapy.

Limitations: Fewer trials and smaller patient numbers compared to neoadjuvant meta-analysis; heterogeneity in trial designs and chemotherapy regimens; timing of chemotherapy administration varied.

ABC Meta-analysis Collaborators Group (Adjuvant Chemotherapy – 2022 Update)

Journal/Author: European Urology (Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group, 2022 Jan); PubMed

Design: Systematic review and meta-analysis of individual participant data from randomized controlled trials evaluating adjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer.

Population: Updated analysis incorporating more recent trials and longer follow-up data.

Primary Outcome: Overall survival.

• Result: The updated meta-analysis confirmed a benefit of adjuvant cisplatin-based chemotherapy, providing stronger evidence than the 2005 analysis.

Significance: This contemporary update strengthens the evidence base for adjuvant chemotherapy in patients who did not receive neoadjuvant therapy and have high-risk pathologic features after cystectomy.

Limitations: Practice patterns have shifted toward neoadjuvant rather than adjuvant chemotherapy, limiting the applicability of these data to modern treatment algorithms where neoadjuvant therapy is standard.

Kronstedt et al. (Early Adjuvant Chemotherapy Meta-analysis)

Journal/Author: Urology (Kronstedt S, et al., 2024 Dec); PubMed

Design: Systematic review and meta-analysis evaluating whether earlier administration of adjuvant chemotherapy significantly augments survival rates in muscle-invasive bladder cancer.

Population: Patients with MIBC receiving adjuvant chemotherapy after radical cystectomy.

Primary Outcome: Overall survival.

• Result: Two primary cutoffs were employed: 45 days and 90 days. Immediate adjuvant chemotherapy was associated with improved survival compared to delayed administration.

Conclusion: Earlier administration of adjuvant chemotherapy improves survival outcomes, supporting prompt initiation of therapy in eligible patients.

Limitations: Retrospective analysis of pooled data; optimal timing cutoff remains debated; applicability to contemporary practice where neoadjuvant therapy is standard.

Koehne et al. (Adjuvant Chemotherapy in Histologic Subtype Bladder Cancer)

Journal/Author: Clinical Genitourinary Cancer (Koehne EL, et al., 2024 Jun); PubMed

Design: Retrospective cohort study characterizing the use of adjuvant chemotherapy in patients with histologic subtype bladder cancer (HSBC) after radical cystectomy.

Population: Patients with HSBC and conventional urothelial carcinoma undergoing radical cystectomy.

Key Findings:

• Patients with HSBC suffer worse outcomes than those with conventional urothelial carcinoma.

• Adjuvant chemotherapy use and its association with survival were characterized in this population.

Significance: This study addresses the important question of whether adjuvant chemotherapy benefits patients with variant histology, who are often excluded from clinical trials.

Limitations: Retrospective design; selection bias; heterogeneous histologic subtypes.

🔬 MUSCLE-INVASIVE BLADDER CANCER (MIBC) – CHEMORADIOTHERAPY & BLADDER PRESERVATION

BC2001 Trial (Chemoradiotherapy for MIBC)

Journal/Author: New England Journal of Medicine (James ND, et al., 2012); Institute of Cancer Research

Design: Largest randomized trial in the field of chemoradiotherapy for muscle-invasive bladder cancer. Phase 3 study evaluating the addition of synchronous chemotherapy to radiotherapy.

Population: Patients with muscle-invasive bladder cancer treated with radical radiotherapy or chemoradiotherapy.

Primary Outcome: Invasive bladder cancer relapse rates.

• Result: Low-dose synchronous chemotherapy with 5FU and mitomycin C reduced invasive bladder cancer relapse rates by 43%.

Conclusion: This landmark, practice-changing trial established chemoradiotherapy as a standard bladder-sparing approach.

Limitations: Despite the reduction in relapses, substantial numbers of patients remain resistant to therapy or relapse either in the bladder or with metastases.

RAD-IO Trial (Durvalumab + Chemoradiotherapy)

Journal/Author: Institute of Cancer Research

Design: Phase 2 trial evaluating synchronous chemoradiotherapy (per BC2001 schedule) with and without prior, synchronous, and adjuvant durvalumab (anti-PD-L1).

Population: Patients with muscle-invasive bladder cancer treated with curative-intent chemoradiotherapy.

Rationale: Tests whether adding durvalumab to standard chemoradiotherapy can further improve outcomes.

Status: Ongoing.

🔬 MUSCLE-INVASIVE BLADDER CANCER (MIBC) – PERIOPERATIVE IMMUNOTHERAPY & ADCs

NIAGARA (Perioperative Durvalumab + Neoadjuvant Chemotherapy)

Journal/Author: New England Journal of Medicine (Powles T, et al., 2024); ASCO Daily News; ESMO Daily Reporter

Design: Phase 3 randomized, open-label trial evaluating perioperative durvalumab (anti-PD-L1) with neoadjuvant gemcitabine-cisplatin (GC) chemotherapy.

Population: 1,063 patients with MIBC eligible for cisplatin and planned for radical cystectomy. Importantly, enrolled patients with CrCl as low as 40 mL/min and permitted split-dose cisplatin, broadening eligibility.

Primary Outcomes: Event-free survival (EFS) and pathological complete response (pCR).

• EFS: HR 0.68 (95% CI 0.56-0.82; P < 0.0001) favoring durvalumab arm.

• pCR (primary analysis): 33.8% vs. 25.8%; did not meet prespecified α threshold (P = 0.0038).

• pCR (reanalysis including additional samples): 37.3% vs. 27.5%; P = 0.0005.

Key Secondary Outcomes:

• Overall survival: HR 0.75 (95% CI 0.59-0.93; P = 0.0106).

• Metastasis-free survival: HR 0.67 (P < 0.001).

• Disease-specific survival: HR 0.69 (P = 0.008).

• Cystectomy completion: 88% (durvalumab) vs. 83% (control).

• Safety: No new concerns; no delays in surgery or increased complications.

Conclusion: NIAGARA is the first phase 3 trial to demonstrate that adding perioperative immunotherapy to neoadjuvant chemotherapy significantly improves EFS and OS in MIBC, representing a new standard of care for cisplatin-eligible patients.

Limitations: Only 72% initiated adjuvant durvalumab, and only 54% completed all 8 cycles; relative contributions of neoadjuvant vs. adjuvant phases unclear.

KEYNOTE-905/EV-303 (Perioperative EV + Pembrolizumab in Cisplatin-Ineligible MIBC)

Journal/Author: ESMO 2025 Presidential Symposium (Vulsteke C, et al.); MedPage Today

Design: Phase 3 randomized trial evaluating perioperative enfortumab vedotin (EV) plus pembrolizumab in cisplatin-ineligible patients with MIBC.

Population: 344 patients with MIBC (cT2-T4aN0M0 or T1-T4aN1M0) who were cisplatin-ineligible or refused cisplatin. Median age 73-74 years.

Primary Outcome: Event-free survival (EFS) by central review.

• Median EFS: Not reached (EV-P) vs. 15.7 months (control); HR 0.40 (95% CI 0.28-0.57; P < 0.0001).

• 2-year EFS: 74% (EV-P) vs. 39.4% (control).

Key Secondary Outcomes:

• Overall survival: Median 41.7 months (control) vs. not reached (EV-P); HR 0.50 (95% CI 0.33-0.74; P = 0.0002).

• 2-year OS: 79.7% vs. 63.1%.

• Pathological complete response (pCR): 57.1% (EV-P) vs. 8.6% (control); P < 0.000001.

• Grade ≥3 TEAEs: 71.3% vs. 45.9%.

Conclusion: Perioperative EV-pembrolizumab dramatically improves EFS, OS, and pCR in cisplatin-ineligible MIBC, representing a new standard of care for this population with high unmet medical need.

Limitations: Adjuvant nivolumab was not available during much of the trial; contribution of neoadjuvant vs. adjuvant phases unclear.

SunRISe-4 (TAR-200 + Cetrelimab Neoadjuvant Therapy)

Journal/Author: The Lancet Oncology (Necchi A, et al., 2025); Pharmacy Times

Design: Randomized, open-label, phase 2 trial across 109 centers in 10 countries. Patients randomized to TAR-200 (intravesical gemcitabine delivery system) plus cetrelimab (anti-PD-1) vs. cetrelimab monotherapy.

Population: 122 patients with cisplatin-ineligible MIBC (cT2-cT4 N0M0) scheduled for radical cystectomy. Mean age 70.7 years.

Primary Outcome: Pathological complete response (pCR).

• Result: 38% (TAR-200 + cetrelimab) vs. 24% (cetrelimab monotherapy).

Key Secondary Outcomes:

• Pathologic downstaging: >50% (combination) vs. 44% (monotherapy).

• 1-year relapse-free survival: 77% vs. 66%.

• Safety: No new signals; most grade 3-4 AEs were local urinary symptoms.

Conclusion: Neoadjuvant TAR-200 plus cetrelimab demonstrates promising pCR rates with manageable safety in cisplatin-ineligible MIBC.

NEOBLADE (Nintedanib + Neoadjuvant Chemotherapy)

Journal/Author: The Lancet Oncology (Hussain SA, et al., 2022)

Design: Parallel-arm, double-blind, randomized, placebo-controlled, phase 2 trial across 15 UK hospitals. Patients randomized (1:1) to nintedanib or placebo, in addition to standard neoadjuvant gemcitabine-cisplatin chemotherapy.

Population: 120 patients with locally advanced muscle-invasive bladder cancer, ECOG performance status 0-1.

Primary Outcome: Pathological complete response rate.

• Result: 37% (21/57) in nintedanib group vs. 32% (20/63) in placebo group; OR 1.25 (70% CI 0.84-1.87; p=0.28) – NOT SIGNIFICANT.

Conclusion: The addition of nintedanib to neoadjuvant chemotherapy was safe but did not improve pCR rates, and does not support further investigation.

Limitations: Phase 2 design with modest sample size; increased hematologic toxicity without corresponding benefit.

RC48 + Immunotherapy (Real-World Neoadjuvant Study)

Journal/Author: NPJ Precision Oncology (Guo X, et al., 2025)

Design: Multicenter, retrospective real-world study evaluating disitamab vedotin (RC48, an anti-HER2 antibody-drug conjugate) plus PD-1 inhibitors as neoadjuvant therapy.

Population: 25 patients with localized MIBC (cT2-4aN0-2M0) who received at least four cycles of RC48 with toripalimab, tislelizumab, or pembrolizumab, followed by radical cystectomy.

Primary Outcome: Pathological complete response rate.

• Result: 48%.

Key Secondary Outcomes:

• Pathological downstaging rate: 88%.

• 12-month disease-free survival: 91.5%.

• 12-month overall survival: 100% (median follow-up 17.0 months).

• HER2 overexpression (IHC 3+): Significantly associated with higher response (OR 6.75; 95% CI 1.16-39.20; p=0.033).

Conclusion: RC48 combined with PD-1 inhibitors demonstrates promising efficacy as neoadjuvant therapy for localized MIBC, with a 48% pCR rate.

Limitations: Retrospective design with small sample size; no control arm; short follow-up.

🔬 ADVANCED/METASTATIC UROTHELIAL CANCER

Foundational Chemotherapy Trials (Loehrer et al., 1992)

Journal/Author: Journal of Clinical Oncology (Loehrer PJ, et al., 1992); cited in

Design: Randomized comparison of cisplatin alone versus cisplatin in combination with methotrexate, vinblastine, and doxorubicin (MVAC) in patients with metastatic urothelial carcinoma.

Population: Patients with advanced/metastatic urothelial cancer.

Key Findings:

• Combination chemotherapy (MVAC) demonstrated superior response rates and survival compared to cisplatin alone.

• Established platinum-based combination chemotherapy as the standard of care for advanced bladder cancer for decades.

Limitations: Significant toxicity with MVAC regimen; largely replaced by gemcitabine-cisplatin in contemporary practice.

Gemcitabine + Cisplatin vs. MVAC (Phase III)

Journal/Author: Journal of Clinical Oncology (von der Maase H, et al., 2000); cited in

Design: Phase III randomized trial comparing gemcitabine plus cisplatin (GC) versus MVAC in patients with advanced urothelial cancer.

Population: Patients with advanced/metastatic urothelial carcinoma.

Key Findings:

• GC demonstrated comparable efficacy to MVAC with better tolerability.

• GC became the most commonly used first-line regimen for advanced bladder cancer.

Significance: This trial established the standard of care for first-line treatment of advanced bladder cancer that would persist for over two decades until the EV-302 trial.

JAVELIN Bladder 100 (Avelumab Maintenance)

Journal/Author: New England Journal of Medicine (Powles T, et al., 2020); OncLive

Design: Phase 3 randomized trial comparing maintenance avelumab (anti-PD-L1) plus best supportive care versus best supportive care alone after first-line chemotherapy.

Population: Patients with metastatic urothelial cancer who had not progressed after 4-6 cycles of gemcitabine-cisplatin or gemcitabine-carboplatin.

Primary Outcome: Overall survival.

• Result: Significant OS advantage with maintenance avelumab compared to observation.

Conclusion: This landmark trial established immunotherapy as maintenance therapy after upfront chemotherapy as a new standard of care for metastatic bladder cancer.

EV-302/KEYNOTE-A39 (Enfortumab Vedotin + Pembrolizumab in First-Line Metastatic UC)

Journal/Author: New England Journal of Medicine (Powles T, et al., 2024); Johns Hopkins Medicine

Design: Phase 3 randomized trial comparing enfortumab vedotin plus pembrolizumab (EV-P) versus platinum-based chemotherapy (gemcitabine-cisplatin or gemcitabine-carboplatin).

Population: Nearly 900 patients with previously untreated locally advanced or metastatic urothelial cancer across 185 centers in 25 countries.

Primary Outcome: Overall survival and progression-free survival.

• Result: Patients treated with EV-P lived almost twice as long compared to those treated with chemotherapy.

• Time to cancer progression: Significantly longer in EV-P group.

Key Secondary Outcomes:

• Better tolerability: EV-P better tolerated than chemotherapy due to targeted mechanism.

• FDA approval: Based on these results, EV-P approved for first-line treatment of advanced urothelial cancer.

Conclusion: EV-P represents a “practice-changing” advance, for the first time outperforming the decades-old standard of platinum-based chemotherapy in the first-line metastatic setting.

Limitations: Skin reactions common (~50% of patients) due to Nectin-4 expression in skin; requires management expertise.

EV-103/KEYNOTE-869 (EV + Pembrolizumab in Cisplatin-Ineligible Metastatic UC)

Journal/Author: Journal of Clinical Oncology (Hoimes CJ, et al., 2022); OncLive

Design: Phase 2 dose-escalation and -expansion trial with multiple arms, focusing on frontline EV plus pembrolizumab in cisplatin-ineligible patients.

Population: Patients with metastatic bladder cancer ineligible for cisplatin-based chemotherapy.

Primary Outcomes: Safety and tolerability; objective response rate.

• ORR: 73.3% – substantially higher than historical 30-40% with conventional chemotherapy.

• Median OS: 26.1 months – approximately 30% improvement over traditional chemotherapy.

Conclusion: EV-pembrolizumab established a new therapeutic option with superior efficacy for cisplatin-ineligible metastatic bladder cancer, leading to accelerated approval.

CheckMate-901 (Nivolumab + Gemcitabine-Cisplatin in First-Line Metastatic UC)

Journal/Author: New England Journal of Medicine (van der Heijden MS, et al., 2023); ASCO Daily News

Design: Phase 3 randomized trial evaluating nivolumab plus gemcitabine-cisplatin (GC) versus GC alone in first-line metastatic urothelial cancer.

Population: Patients with previously untreated metastatic UC.

Key Findings:

• Complete response rate: 21.7% (nivolumab + GC) vs. 11.8% (GC alone).

• Duration of complete responses: 37.1 months vs. 13.2 months.

• Lymph node-only metastases subgroup: Strikingly higher response rates (81.5% vs. 64.3%), PFS (30.5 vs. 8.8 months; HR 0.38), and OS (46.3 vs. 24.9 months; HR 0.58).

Conclusion: Nivolumab plus chemotherapy improves outcomes in first-line metastatic UC, complementing the EV-P paradigm.

KEYNOTE-045 (Pembrolizumab vs. Chemotherapy in Platinum-Refractory UC)

Journal/Author: New England Journal of Medicine (Bellmunt J, et al., 2017)

Design: Phase 3 randomized trial comparing pembrolizumab versus investigator’s choice chemotherapy (paclitaxel, docetaxel, or vinflunine) in patients with platinum-refractory metastatic urothelial carcinoma.

Population: Patients with advanced urothelial cancer that progressed after platinum-based chemotherapy.

Primary Outcome: Overall survival.

• Result: Pembrolizumab significantly improved OS compared to chemotherapy, leading to FDA approval.

Conclusion: This foundational trial established immunotherapy as standard of care in the second-line setting for advanced bladder cancer.

EV-301 (Enfortumab Vedotin vs. Chemotherapy in Post-Platinum/PD-1 UC)

Journal/Author: New England Journal of Medicine (Powles T, et al., 2021)

Design: Phase 3 randomized trial comparing enfortumab vedotin versus investigator’s choice chemotherapy in patients previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors.

Population: Patients with advanced urothelial cancer that progressed after both platinum chemotherapy and immunotherapy.

Primary Outcome: Overall survival.

• Result: EV significantly improved OS compared to chemotherapy, establishing it as standard of care in this setting.

🔬 ONGOING AND FUTURE DIRECTIONS

Ongoing Phase 3 Trials in MIBC

Bladder Preservation and Biomarker-Driven Trials

📊 SUMMARY OF KEY THERAPEUTIC SHIFTS IN BLADDER CANCER

LANDMARK UPPER TRACT UROTHELIAL CARCINOMA (UTUC) TRIALS

🔬 CHEMOABLATION WITH MITOMYCIN GEL (UGN-101/Jelmyto)

OLYMPUS Trial (Phase 3 Primary Chemoablation for Low-Grade UTUC)

Journal/Author: Journal of Urology (Kleinmann N, et al., 2020); Yale Medicine

Design: Phase 3, multicenter, open-label, single-arm trial evaluating the efficacy and safety of UGN-101, a mitomycin-containing reverse thermal gel, as primary chemoablative therapy.

Population: 71 patients (68% male, 87% White, median age 71 years) with low-grade UTUC. Patients had biopsy-proven, primary or recurrent disease and were candidates for ablative treatment .

Treatment Protocol: Six weekly instillations of UGN-101 (4 mg mitomycin per mL) administered via retrograde ureteral catheter or percutaneous nephrostomy tube. The gel is liquid at cold temperatures and solidifies at body temperature, providing sustained drug contact with the urothelium for 4-6 hours before being cleared in urine .

Primary Outcome: Complete response (CR) rate at 4-6 weeks after the last dose (approximately 3 months after study start).

• Result: 59% (42/71 patients) achieved CR.

Key Secondary Outcomes:

• 12-month CR rate: Of the 42 patients with CR at 3 months who received monthly maintenance instillations (up to 11 additional doses), 56% remained tumor-free at 12 months .

• Median duration of response (DoR): 47.8 months (95% CI 13.0–not estimable) .

• Long-term follow-up (median 53.3 months): Among 20 patients in the long-term follow-up study (BL007), 75% had no evidence of recurrence at last follow-up .

• Disease progression: No reported progressions to high-grade disease .

• Safety: Common adverse events included ureteral stenosis/swelling (reported separately), UTI, hematuria, nausea, dysuria, and flank pain. Serious AEs occurred in a minority, with no treatment-related deaths .

Conclusion: UGN-101 provides clinically meaningful complete response rates with remarkable durability (median DoR nearly 4 years) in patients with low-grade UTUC, offering a kidney-sparing alternative to radical nephroureterectomy or repeat endoscopic ablations . Based on these results, the FDA approved UGN-101 (Jelmyto) in 2020 for the treatment of low-grade UTUC .

Limitations: Single-arm design without randomized comparator; open-label; relatively small sample size; long-term data available for only a subset of patients; requires specialized administration via ureteral catheter or nephrostomy tube.

Take-home Message: Mitomycin reverse thermal gel chemoablation is a highly effective, durable, and FDA-approved kidney-sparing option for low-grade UTUC, achieving complete response in nearly 60% of patients with responses lasting a median of almost 4 years .

Imperative Indications and High-Grade Disease (UGN-101 Multicenter Registry)

Journal/Author: European Urology Focus (Rose KM, et al., 2023); PubMed

Design: Multicenter, retrospective registry analysis from 15 high-volume academic and community centers evaluating UGN-101 in patients with imperative indications for renal preservation.

Population: 48 patients (52 renal units) treated with UGN-101 for imperative indications, defined as:

• Solitary kidney (56%)

• Bilateral UTUC (21%)

• Chronic kidney disease (CKD) with GFR <30 mL/min (12%)

• Unfit for or unwilling to undergo radical nephroureterectomy (12%)

• Twelve renal units had biopsy-proven high-grade papillary disease.

Key Findings:

• Tumor status before induction: 34% had tumors completely ablated before induction; 66% had tumor present.

• Post-induction outcomes: 40% (17 patients) had no evidence of disease (NED) on ureteroscopy; of these, 88% maintained NED at median follow-up of 10.8 months.

• High-grade cohort: 45% (5 patients) had NED at initial post-induction evaluation.

• Safety: Adverse events included pyelonephritis (8%), ureteral stenosis (8%), anemia (6%), and acute renal failure (4%).

Conclusion: Intracavitary UGN-101 shows promise as a kidney-sparing treatment for patients with imperative indications, including those with high-grade disease, potentially delaying time to nephroureterectomy and the morbidity of hemodialysis .

Limitations: Retrospective design; selection bias; modest sample size; short follow-up; heterogeneous patient population.

Take-home Message: For patients with imperative indications who cannot undergo nephroureterectomy, mitomycin gel chemoablation offers a viable kidney-sparing option, with nearly half of high-grade patients achieving no evidence of disease after treatment .

🔬 BCG AND INTRACAVITARY THERAPY FOR HIGH-GRADE UTUC

Massari et al. (BCG Efficacy After Nephroureterectomy)

Journal/Author: Urologic Oncology: Seminars and Original Investigations (Massari M, et al., 2024)

Design: Retrospective study evaluating the efficacy of BCG for non-muscle-invasive bladder cancer (NMIBC) in patients with a history of nephroureterectomy for UTUC.

Population: Patients treated with BCG for NMIBC, stratified by presence or absence of prior UTUC.

Key Findings:

• History of UTUC is associated with reduced efficacy of BCG for subsequent NMIBC.

• Shorter time to disease recurrence after BCG in patients with prior UTUC.

• Genomic differences between UTUC and bladder UC may explain differential BCG responsiveness .

Conclusion: Alternative adjuvant therapy options should be evaluated in patients with prior UTUC, as they demonstrate inferior responses to BCG.

Limitations: Retrospective design; modest sample size; single-institution.

Take-home Message: Patients with a history of UTUC have worse outcomes with BCG for subsequent bladder cancer, suggesting that alternative endoluminal therapies (e.g., gemcitabine/docetaxel) may be preferred .

McElree et al. (AUA 2024: Gemcitabine/Docetaxel vs. BCG for High-Grade UTUC)

Journal/Author: UroToday (McElree I, et al., AUA 2024)

Design: Retrospective comparative study evaluating sequential endoluminal gemcitabine plus docetaxel versus BCG for the treatment of high-grade UTUC, including carcinoma in situ (CIS).

Population: 53 patients (65 upper tract units): 34 treated with gemcitabine/docetaxel, 31 treated with BCG. Treatment administered via percutaneous nephrostomy tube or retrograde ureteral catheter.

Treatment Protocols:

• Gemcitabine/docetaxel: Six weekly induction instillations of gemcitabine (1 gm) + docetaxel (37.5 mg), followed by monthly maintenance for 6 months.

• BCG: Six weekly induction instillations (1 vial +/- IFNa-2b), followed by a single 3-week mini-cycle maintenance.

Key Findings:

• 2-year high-grade recurrence-free survival (HG-RFS): BCG 61% vs. Gem/Doce 54%—similar between groups.

• Nephroureterectomy-free survival at 2 years: BCG 89% vs. Gem/Doce 100%.

• Progression-free survival at 2 years: BCG 84% vs. Gem/Doce 93%.

• Route of administration: Antegrade instillation via nephrostomy tube was associated with >3-fold increased risk of recurrence compared to retrograde instillation (HR 3.89, 95% CI 1.59-9.53, p<0.01).

• Adverse events: Similar rates between groups; grade ≥3 AEs in 11% (BCG) vs. 7.7% (Gem/Doce); p=0.12.

Conclusion: Endoluminal gemcitabine/docetaxel and BCG demonstrate similar oncological outcomes and adverse event rates for high-grade UTUC, supporting gemcitabine/docetaxel as an alternative to BCG .

Limitations: Retrospective design; relatively small sample size; selection bias; short follow-up (27 months for Gem/Doce vs. 58 months for BCG); requires prospective validation.

Take-home Message: Gemcitabine/docetaxel combination therapy offers comparable efficacy to BCG for high-grade UTUC and should be considered a viable alternative, particularly given the ongoing BCG shortage .

Pembrolizumab + BCG for High-Grade NMI-UTUC (NCT03504163)

Journal/Author: MedPath (NCT03504163); NIH PMC Table

Design: Phase 2, open-label, single-arm trial evaluating the combination of pembrolizumab (anti-PD-1) plus BCG as first-line therapy for high-risk, BCG-naïve patients.

Population: Exploratory cohort for high-grade non-muscle-invasive UTUC (estimated enrollment 37 patients). Inclusion criteria:

• Histologically confirmed UTUC (Tis, Ta, or T1) in renal pelvis.

• Refusal of radical nephroureterectomy.

• No prior BCG to the involved renal unit (prior intravesical BCG for bladder cancer allowed).

Treatment Protocol:

• Pembrolizumab: 400 mg IV every 6 weeks for 9 doses (48 weeks).

• BCG: Once-weekly for 6 consecutive weeks as induction, administered via percutaneous nephrostomy tube in antegrade fashion, starting week 3 after first pembrolizumab dose.

Primary Outcome: Disease-free survival at 6 months.

Rationale: The combination of two distinct immunotherapies (PD-1 blockade + BCG) may have additive or synergistic activity in urothelial cancer, with pembrolizumab priming T cells to enhance BCG effects .

Status: Recruiting; estimated primary completion April 2025.

Take-home Message: This first-in-human trial of pembrolizumab plus BCG for high-grade UTUC will define the safety and efficacy of combining systemic immunotherapy with endoluminal BCG in the nephron-sparing setting.

📊 SUMMARY OF KEY THERAPEUTIC SHIFTS IN UTUC (UPDATED)

LANDMARK RENAL CELL CARCINOMA (RCC) TRIALS

🔬 SURGICAL MANAGEMENT: RADICAL VS. PARTIAL NEPHRECTOMY

EORTC 30904 (Phase 3 Randomized Trial: Nephron-Sparing vs. Radical Nephrectomy)

Journal/Author: European Urology (Van Poppel H, et al., 2011)

Design: Prospective, randomized, non-inferiority phase 3 trial conducted by the European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group. This is the only randomized trial comparing elective nephron-sparing surgery (NSS) and radical nephrectomy (RN) for low-stage RCC.

Population: 541 patients with small (≤5 cm), solitary, T1-T2 N0 M0 renal tumors suspicious for RCC and a normal contralateral kidney. Patients were randomized to radical nephrectomy or nephron-sparing surgery. Accrual was slower than anticipated, and only 42% of the planned sample size was reached.

Primary Outcome: Overall survival (OS) – intention-to-treat analysis.

• 10-year OS: 81.1% (RN) vs. 75.7% (NSS); hazard ratio not provided but difference was statistically significant (p = 0.03), favoring radical nephrectomy.

Key Secondary Outcomes:

• 10-year OS in patients with histologically confirmed RCC: Trend favoring RN (81.1% vs. 77.4%), but not statistically significant (p = 0.07).

• Disease-free survival: Excellent with both techniques, confirming oncologic equivalence for cancer control.

• Non-cancer-related mortality: No difference observed between groups, contrary to retrospective studies suggesting RN increases cardiovascular risk .

Conclusion: This landmark trial confirms the oncological safety of nephron-sparing surgery for small renal tumors. However, the unexpected overall survival advantage for radical nephrectomy in the intention-to-treat analysis contradicts extensive retrospective data and remains controversial.

Take-home Message: Partial nephrectomy is oncologically safe for small renal masses and preserves renal function, but this randomized trial did not confirm the survival advantage seen in retrospective series. Patient selection, surgical expertise, and comorbidity management are critical determinants of long-term outcomes .

Limitations: The trial closed early due to poor accrual, resulting in a smaller-than-planned sample size and potential selection bias. Comorbidities were not assessed using standardized scores, and detailed surgical data (warm ischemia time, parenchymal preservation) were not collected.

🔬 ACTIVE SURVEILLANCE FOR SMALL RENAL MASSES

Multicenter Study of Active Surveillance for Small Renal Masses (Ajami et al.)

Journal/Author: Urologic Oncology (Ajami T, et al., 2025)

Design: Multicenter retrospective review of active surveillance (AS) practices across five tertiary Spanish centers.

Population: 384 patients with small renal masses (SRMs) suspicious for RCC managed with AS from January 2012 to September 2024.

Key Findings:

• Mean initial tumor size: 20.5 mm.

• Mean follow-up period: 43 months.

• Average growth rate (GR) across cohort: 1.4 mm/year.

• Deferred intervention rate: 15% (59 patients).

• Treatment modalities: Partial nephrectomy (56%), radical nephrectomy (16%), radiofrequency ablation (28%).

• Predictors of deferred intervention: Age, tumor size, and tumor growth rate.

• Pathological outcomes: High-grade clear cell RCC was found in 43.5% of patients with GR >5 mm/year, compared to 19.4% oncocytomas in slow-growing lesions.

• Oncological outcomes: No disease progression or cancer-specific deaths observed during follow-up.

Conclusion: Active surveillance is a valid and safe initial management strategy for small renal masses. Clinical factors including age, tumor size, growth kinetics, and selective use of biopsy can inform decisions about deferred intervention without compromising oncological outcomes.

Take-home Message: For appropriately selected patients with small renal masses, active surveillance with regular imaging (annual growth assessment) avoids overtreatment while maintaining oncological safety. Growth rate >5 mm/year or size exceeding 30 mm may trigger consideration for intervention.

Limitations: Retrospective design, lack of standardized surveillance protocols, and absence of centralized pathology review.

🔬 LYMPH NODE DISSECTION IN RCC

EORTC 30881 (Radical Nephrectomy With or Without Lymph Node Dissection)

Journal/Author: European Urology (Blom JH, et al., 2009)

Context: This foundational trial demonstrated no survival benefit for routine lymph node dissection (LND) in clinically node-negative patients, leading to its omission in contemporary guidelines. The trial predominantly included low-risk patients with a low incidence of pathological nodal involvement (4.0%), rendering it underpowered to evaluate LND efficacy in high-risk populations.

Take-home Message: Routine LND is not indicated for low-risk RCC based on this level 1 evidence.

RECLND Trial (Template Lymph Node Dissection in High-Risk RCC) – Ongoing

Journal/Author: ICHGCP (Tianjin Medical University Second Hospital, 2025)

Design: Prospective, open-label, multicenter, phase 3 randomized controlled trial evaluating the role of template-based LND in high-risk RCC.

Population: 220 patients with high-risk RCC (cT3-4 N0-1 M0 or M1 rendered no evidence of disease after local therapy). High-risk features include advanced T-stage, large tumor size, sarcomatoid differentiation, or venous thrombus.

Intervention:

• Arm A (Experimental): Radical nephrectomy (RN) plus template LND.

  • Left-sided tumors: Removal of lymphatic tissue anterior and lateral to the aorta from diaphragmatic crus to aortic bifurcation, including renal hilar nodes.

  • Right-sided tumors: Removal of paracaval, precaval, and interaortocaval nodes from hepatic edge of IVC to iliac bifurcation.

• Arm B (Control): RN with resection only of radiologically or intraoperatively detected lymph nodes ≥1 cm.

Primary Outcomes: Disease-free survival (DFS), overall survival (OS), surgical safety.

Rationale: Robust retrospective evidence suggests that in patients with high-risk features, more extensive LND may confer therapeutic benefit by eradicating micrometastatic disease.

Take-home Message: While routine LND is not indicated for low-risk RCC, its role in high-risk disease remains uncertain. The RECLND trial will provide level 1 evidence on whether template-based LND improves oncologic outcomes in appropriately selected high-risk patients.

🔬 ADJUVANT THERAPY (POST-NEPHRECTOMY)

KEYNOTE-564 (Adjuvant Pembrolizumab in High-Risk RCC)

Journal/Author: New England Journal of Medicine (Choueiri TK, et al., 2021); NEJM (Choueiri TK, et al., 2024 – OS update)

Design: Phase 3 randomized, double-blind, placebo-controlled trial evaluating adjuvant pembrolizumab (anti-PD-1) versus placebo following nephrectomy in patients with RCC at high risk of recurrence.

Population: 994 patients with clear-cell RCC (ccRCC) at intermediate-high or high risk of recurrence after nephrectomy, or those with resected metastatic disease. High-risk ccRCC was defined as pT2 (grade 4 or sarcomatoid histology), ≥pT3, pTxN+, or M1 with no evidence of disease after resection .

Primary Outcome: Disease-free survival (DFS).

• First interim analysis (median follow-up 24.1 months): Pembrolizumab reduced risk of disease recurrence or death by 32% (HR 0.68; 95% CI 0.53-0.87; P = 0.001).

Key Secondary Outcomes:

• Overall survival (OS) at final analysis (median follow-up 57.2 months): 38% reduction in risk of death with pembrolizumab (HR 0.62; 95% CI 0.44-0.87; P = 0.005) .

• 48-month OS rate: 91.2% (pembrolizumab) vs. 86.0% (placebo).

• Benefit observed across key subgroups.

Safety:

• Treatment-related AEs (any grade): 79.1% (pembrolizumab) vs. 53.0% (placebo).

• Grade 3-4 TRAEs: 18.6% vs. 1.2%.

Conclusion: This is the first phase 3 adjuvant trial to demonstrate improved overall survival in RCC. Adjuvant pembrolizumab is now standard of care for patients with high-risk RCC after nephrectomy .

Take-home Message: Adjuvant pembrolizumab for one year after nephrectomy significantly improves both disease-free and overall survival in high-risk RCC, representing a practice-changing advance after nearly 50 years of failed adjuvant trials .

S-TRAC Trial (Adjuvant Sunitinib)

Journal/Author: New England Journal of Medicine (Ravaud A, et al., 2016)

Design: Phase 3 randomized trial comparing adjuvant sunitinib (a VEGF-TKI) versus placebo after nephrectomy.

Population: Patients with high-risk locoregional ccRCC.

Primary Outcome: Disease-free survival.

• Result: Modest improvement in DFS with sunitinib, leading to FDA approval.

Key Secondary Outcomes: No overall survival benefit demonstrated. Subsequent meta-analyses failed to show a benefit for adjuvant VEGF inhibitors .

Conclusion: While S-TRAC led to FDA approval, the high rate of toxicity and lack of OS benefit precluded its widespread adoption in clinical practice .

Take-home Message: Sunitinib remains the only TKI approved in the adjuvant setting, but lack of OS benefit and significant toxicity have limited its adoption compared to pembrolizumab .

Negative Adjuvant Immunotherapy Trials

CheckMate 914 (Nivolumab + Ipilimumab)

• Journal/Author: The Lancet (Motzer RJ, et al., 2023)

• Result: Failed to show survival benefit, likely due to differences in study design and inclusion criteria for high-risk disease .

IMmotion010 (Atezolizumab)

• Journal/Author: The Lancet (Pal SK, et al., 2022)

• Result: Negative trial; no survival benefit demonstrated .

PROSPER ECOG-ACRIN EA8143 (Perioperative Nivolumab)

• Journal/Author: Lancet Oncology (Allaf ME, et al., 2024)

• Design: Phase 3 randomized, open-label trial evaluating perioperative nivolumab (neoadjuvant + adjuvant) versus surgery alone followed by surveillance.

• Population: 819 patients with high-risk RCC, including selected patients with oligometastatic disease rendered disease-free.

• Primary Outcome: Recurrence-free survival (RFS). HR 0.94 (95% CI 0.74-1.21); p = 0.32 – NOT SIGNIFICANT. Trial stopped at planned interim analysis due to futility .

• Take-home Message: Perioperative nivolumab did not improve RFS in high-risk RCC, contrasting with KEYNOTE-564 and highlighting the importance of timing, duration, and patient selection.

Ongoing Adjuvant/Perioperative Trials

🔬 ADVANCED/METASTATIC CLEAR CELL RCC (FIRST-LINE COMBINATION THERAPIES)

COMPARZ Trial (Pazopanib vs. Sunitinib Head-to-Head)

Journal/Author: Journal of Clinical Oncology (Motzer RJ, et al., 2013); ESMO 2012 presentation

Design: Phase 3, randomized, open-label, non-inferiority trial directly comparing pazopanib and sunitinib in first-line metastatic RCC.

Population: 1,110 patients with treatment-naïve metastatic RCC randomized to pazopanib 800 mg daily or sunitinib 50 mg daily (4 weeks on/2 weeks off).

Primary Outcome: Progression-free survival (non-inferiority).

• Median PFS: 8.4 months (pazopanib) vs. 9.5 months (sunitinib).

• Hazard ratio (HR): 1.047 – non-inferiority demonstrated.

Key Secondary Outcomes:

• Objective response rate (ORR): 31% (pazopanib) vs. 25% (sunitinib); P = 0.03.

• Median overall survival: 28.4 months (pazopanib) vs. 29.3 months (sunitinib); HR 0.91.

Safety and Tolerability:

• Pazopanib was favored by patients in 11 of 14 quality-of-life categories at 6 months.

• Lower incidence with pazopanib: Fatigue (55% vs. 63%), hand-foot syndrome, stomatitis.

• Higher incidence with pazopanib: Liver enzyme elevation (31% vs. 18%; P < 0.05).

Conclusion: Pazopanib and sunitinib demonstrate comparable efficacy in first-line metastatic RCC. Pazopanib offers a distinct and potentially more favorable side-effect profile, particularly regarding fatigue and hand-foot syndrome, though with increased hepatotoxicity .

Take-home Message: The COMPARZ trial established that pazopanib and sunitinib are therapeutically equivalent, with choice guided by patient comorbidities, toxicity profiles, and preference.

CheckMate 214 (Nivolumab + Ipilimumab)

Journal/Author: New England Journal of Medicine (Motzer RJ, et al., 2018)

Design: Phase 3 randomized trial comparing nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) versus sunitinib in first-line advanced RCC.

Population: Patients with previously untreated advanced ccRCC, stratified by IMDC risk groups.

Primary Outcomes: Overall survival, progression-free survival, and objective response rate in intermediate- and poor-risk patients.

• OS (intermediate/poor-risk): Significant improvement with nivolumab/ipilimumab (HR 0.63; P < 0.001).

• Complete response rate: Dramatically higher with combination (9% vs. 1%).

• 8-year follow-up: 35% of patients alive and 50% of treatment responses ongoing despite previously stopping treatment.

Key Secondary Outcomes:

• Favorable-risk cohort: No OS benefit observed due to high sensitivity to sunitinib.

Conclusion: Nivolumab/ipilimumab established ICI-ICI combination as a standard of care for intermediate/poor-risk advanced RCC, with unprecedented durable responses and treatment-free intervals .

Take-home Message: For intermediate/poor-risk patients, nivolumab/ipilimumab offers the potential for durable complete responses and extended treatment-free survival.

KEYNOTE-426 (Pembrolizumab + Axitinib)

Journal/Author: New England Journal of Medicine (Rini BI, et al., 2019); Nature Medicine (Rini BI, et al., 2025)

Design: Phase 3 randomized trial comparing pembrolizumab (anti-PD-1) plus axitinib (VEGF-TKI) versus sunitinib in first-line advanced RCC.

Population: 861 patients with previously untreated advanced ccRCC across all IMDC risk groups.

Primary Outcomes: Overall survival and progression-free survival.

• First interim analysis: Significant improvements in OS, PFS, and ORR with pembrolizumab/axitinib.

Long-term Follow-up (median 67.2 months):

• Median OS: 47.2 months (pembrolizumab/axitinib) vs. 40.8 months (sunitinib).

• Median PFS: 15.7 months vs. 11.1 months.

• Objective response rate (ORR): 60.6% vs. 39.6%.

Conclusion: Pembrolizumab/axitinib was the first ICI-TKI combination to demonstrate OS benefit in first-line RCC, with sustained efficacy at >5 years follow-up .

Take-home Message: Pembrolizumab plus axitinib provides durable long-term benefits across all IMDC risk groups and remains a standard first-line option with the longest follow-up data among ICI-TKI combinations.

CheckMate 9ER (Nivolumab + Cabozantinib)

Journal/Author: New England Journal of Medicine (Choueiri TK, et al., 2021)

Design: Phase 3 randomized trial comparing nivolumab plus cabozantinib (multi-target TKI) versus sunitinib.

Population: First-line advanced ccRCC across all IMDC risk groups.

Primary Outcome: Progression-free survival.

• Result: Significant improvement in PFS, OS, and ORR compared to sunitinib.

Key Secondary Outcomes: Benefits observed across all risk groups and PD-L1 expression levels.

Conclusion: Nivolumab/cabozantinib established another ICI-TKI standard, with cabozantinib’s unique MET/AXL inhibition providing additional therapeutic targeting.

Take-home Message: Nivolumab plus cabozantinib offers high efficacy with a different toxicity profile (diarrhea, palmar-plantar erythrodysesthesia, hypertension) requiring proactive management.

CLEAR Trial (Lenvatinib + Pembrolizumab)

Journal/Author: New England Journal of Medicine (Motzer R, et al., 2021)

Design: Phase 3 randomized trial with three arms: lenvatinib (TKI) plus pembrolizumab, lenvatinib plus everolimus, or sunitinib alone.

Population: First-line advanced RCC.

Primary Outcome: Progression-free survival.

• Result: Lenvatinib/pembrolizumab significantly improved PFS, OS, and ORR compared to sunitinib.

Key Secondary Outcomes: High ORR (~71%) and complete response rates.

Conclusion: Lenvatinib/pembrolizumab became another first-line standard, with particularly high response rates .

Take-home Message: Lenvatinib/pembrolizumab is associated with the highest objective response rates among first-line combinations, though with distinct toxicity (hypothyroidism, hypertension, fatigue, diarrhea) requiring expertise in management.

JAVELIN Renal 101 (Avelumab + Axitinib)

Journal/Author: New England Journal of Medicine (Motzer RJ, et al., 2019); JITC (2024 meta-analysis)

Design: Phase 3 randomized trial comparing avelumab (anti-PD-L1) plus axitinib versus sunitinib.

Primary Outcome: Progression-free survival.

• Result: Initial data showed PFS benefit.

Long-term Outcome: The final analysis did not show a significant OS improvement compared to other IO combinations .

Take-home Message: Despite initial promise, JAVELIN Renal 101 failed to demonstrate statistically significant OS advantage in final analysis, distinguishing it from other IO-TKI combinations.

Meta-Analysis of First-Line IO Combinations (JITC 2024)

Journal/Author: Journal for ImmunoTherapy of Cancer (2024)

Design: Systematic review and meta-analysis of phase 3 trials comparing IO combinations to sunitinib in first-line mRCC.

Trials Included: CheckMate 214, CheckMate 9ER, KEYNOTE-426, CLEAR, and JAVELIN Renal 101.

Key Findings:

• CLEAR trial (pembrolizumab + lenvatinib) showed the most significantly improved survival as measured by median PFS.

• OS improvement was significant for trials with this coprimary outcome, except for JAVELIN Renal 101.

• The dual IO combinations and IO plus TKI combinations evaluated demonstrated significantly better outcomes than sunitinib, suggesting a potential shift from considering sunitinib as the standard of care for 1L mRCC .

Take-home Message: All four major IO/TKI regimens offer superior OS compared to sunitinib in intermediate- and poor-risk patients. A consistent OS advantage has not been established for the favorable-risk group .

🔬 CYTOREDUCTIVE NEPHRECTOMY (CN) IN METASTATIC RCC

Foundational Trials: SWOG 8949 & EORTC 30947 (Cytokine Era)

Journal/Author: New England Journal of Medicine (Flanigan RC, et al., 2001); The Lancet(Mickisch GH, et al., 2001)

Design: Two parallel phase 3 randomized trials establishing the role of cytoreductive nephrectomy in the era of cytokine therapy (interferon-alfa).

Population:

• SWOG 8949: 241 patients with metastatic RCC, excellent performance status.

• EORTC 30947: A smaller European trial with similar design.

Primary Outcome: Overall survival.

• Combined analysis: HR 0.68 (95% CI 0.51-0.89); 132 fewer all-cause deaths per 1000 patients at 2 years .

Conclusion: These landmark trials established cytoreductive nephrectomy as the standard of care for appropriately selected patients with metastatic RCC receiving cytokine-based immunotherapy.

Take-home Message: In the cytokine era, cytoreductive nephrectomy followed by interferon immunotherapy improves survival. These trials defined the patient characteristics (good performance status, favorable metastatic sites) that predict benefit from surgery .

CARMENA Trial (CN + Sunitinib vs. Sunitinib Alone in TKI Era)

Journal/Author: New England Journal of Medicine (Méjean A, et al., 2018)

Design: Phase 3, open-label, multicenter, randomized non-inferiority trial assessing the role of nephrectomy in patients with metastatic RCC receiving targeted therapy.

Population: 450 patients with clear-cell mRCC, ECOG 0-1. Importantly, 43% had poor IMDC risk disease.

Primary Outcome: Overall survival.

• Median OS (ITT): 18.4 months (sunitinib alone) vs. 13.9 months (nephrectomy + sunitinib); HR 0.89 (95% CI 0.71-1.10) – met non-inferiority criterion .

Key Limitations:

• High proportion of poor-risk patients (43%)—patients who would not typically be offered CN.

• Only 0.7 procedures per center performed.

• Significant contamination: 7% of CN arm never underwent surgery; 17% of sunitinib-only arm received CN.

• Median OS of 13.9 months in CN arm is very short and does not reflect most contemporary CN cohorts .

Conclusion: Sunitinib alone was non-inferior to nephrectomy followed by sunitinib in patients with mRCC, challenging the routine use of upfront cytoreductive nephrectomy in the TKI era .

Take-home Message: CARMENA significantly impacted clinical practice, but results should be interpreted cautiously due to over-representation of poor-risk patients. The EAU guidelines state that MSKCC poor-risk patients should not undergo CN—which was already standard practice .

SURTIME Trial (Immediate vs. Deferred CN in TKI Era)

Journal/Author: European Urology (Bex A, et al., 2019)

Design: Phase 3 randomized trial comparing immediate cytoreductive nephrectomy followed by sunitinib versus three cycles of sunitinib followed by deferred nephrectomy.

Population: 99 patients with mRCC (88% intermediate risk by MSKCC criteria). The trial closed early due to poor accrual.

Primary Outcome: Progression-free survival.

• PFS HR: 0.88 (95% CI 0.56-1.37; P=0.57) – not significant.

Key Secondary Outcomes:

• OS (exploratory analysis): 15 months (immediate) vs. 32 months (deferred); HR 0.57 (95% CI 0.34-0.95; P=0.03) favoring deferred CN .

• Patients receiving systemic therapy: 20% in immediate CN arm never received sunitinib.

Conclusion: While underpowered, SURTIME suggested that deferred CN (after initial systemic therapy) might be associated with improved outcomes compared to immediate CN .

Take-home Message: The results of SURTIME, though hypothesis-generating, have modeled current practice trends favoring initial systemic therapy followed by CN in patients who demonstrate response or stable disease. Initial systemic therapy can serve as a litmus test—a favorable response may prompt re-evaluation for CN .

MD Anderson Risk Model for Patient Selection

Journal/Author: Cancer (MD Anderson Cancer Center)

Design: Retrospective study providing clinicians with 9 objective preoperative clinical variables by which patients with mRCC can be stratified into 3 tiers of risk for increased likelihood of death following CN.

Risk Factors Include:

• Karnofsky performance status <80%

• Hemoglobin <12 g/dL

• Corrected serum calcium >10.2 mg/dL

• Neutrophils >7 x10⁹/L

• Platelets >400k cells/μL

• And others

Risk Groups:

• Low risk (0-1 factors): Consider for CN

• Intermediate risk (2-3 factors): Careful patient selection, individualize recommendations

• High risk (≥4 factors): Should not be offered upfront CN

Take-home Message: Appropriate patient selection using objective criteria has always been paramount in managing mRCC with CN. The MD Anderson model can predict those patients in whom increased surgical risk may exist outside of their tumor biology .

SWOG-1931 (PROBE Trial) – Ongoing

Journal/Author: SWOG Cancer Research Network (expected opening 2020)

Design: Phase 3 randomized trial comparing deferred nephrectomy versus no nephrectomy in patients responding to immunotherapy-based combination regimens.

Population: Patients with newly diagnosed mRCC initially treated with ICI-based therapy. Patients with complete response or progressive disease are off study. Those with partial response or stable disease are randomized to CN or no CN.

Status: Approved for development by NIH; expected to open in 2020 (as of 2019) .

Take-home Message: The PROBE trial will define the role of deferred CN in patients responding to modern immunotherapy, providing much-needed level 1 evidence for the immunotherapy era .

NORDIC-SUN Trial – Ongoing

Design: Scandinavian phase 3 trial evaluating the role of CN in the immunotherapy era.

Status: Ongoing.

🔬 NON-CLEAR CELL RCC

SUNNIFORECAST Trial (Ipilimumab + Nivolumab in Non-Clear Cell RCC)

Journal/Author: CancerNetwork (European phase 3 trial, 2025)

Design: Phase 3 randomized trial – the largest prospective study conducted in non-clear cell RCC population.

Population: Over 300 patients with non-clear cell RCC subtypes (papillary, chromophobe, and others) confirmed by central pathology review. Randomized to ipilimumab + nivolumab versus investigator-chosen standard-of-care.

Primary Outcome: 12-month overall survival rate.

• Result: 78% (immunotherapy combination) vs. 68% (standard-of-care) – met primary endpoint.

Key Secondary Outcomes:

• Median OS: 33 months vs. 25.2 months.

• Objective response rate: 33% vs. 19%.

• Complete response rate: 8% in immunotherapy arm.

Subgroup Analyses: Benefit consistent across histologic subtypes, including papillary RCC.

Conclusion: This landmark trial supports the use of immune-based combinations in non-clear cell RCC, providing evidence for a population often excluded from pivotal ccRCC trials.

Take-home Message: Ipilimumab plus nivolumab improves survival in non-clear cell RCC compared to standard therapies, reinforcing the role of immunotherapy across histologic subtypes and the need for subtype-specific treatment strategies.

MET-Driven Therapies (Cabozantinib in Papillary RCC)

Journal/Author: Current Opinion in Oncology (Srivastava A, et al., 2022)

Design: Multiple phase 2 trials investigating MET inhibitors in papillary RCC, which often harbor MET proto-oncogene pathway alterations.

Key Findings: Cabozantinib (MET, AXL, VEGFR inhibitor) demonstrates encouraging response rates and oncologic outcomes in papillary RCC.

Take-home Message: Papillary RCC treatment is evolving with targeted agents like cabozantinib, moving beyond empiric VEGF inhibition toward biology-driven therapy.

🔬 SARCOMATOID RCC

Subgroup Analyses from CheckMate 214 and KEYNOTE-426

Journal/Author: Journal of Clinical Oncology (subgroup analyses)

Key Findings:

• Sarcomatoid histology remains the only actionable predictive biomarker for immunotherapy.

• CheckMate 214: 61% response to nivolumab/ipilimumab vs. 26% to sunitinib.

• IO combinations are the preferred choice for patients with sarcomatoid features .

Take-home Message: For patients with sarcomatoid features, nivolumab plus ipilimumab is the preferred choice, whereas for those with threatening disease burden, IO/TKI combinations may be prioritized .

🔬 PROGNOSTIC MODELS AND BIOMARKERS

IMDC Model Re-Evaluation in Immunotherapy Era

Journal/Author: JCO Oncology Practice (Grigg CM, et al., 2025); Medscape (Jonasch E, 2026)

Context: The International Metastatic RCC Database Consortium (IMDC) prognostic model, developed in the cytokine/TKI era, has been used for decades to categorize patients into favorable, intermediate, or poor risk categories using a six-factor model.

Key Findings:

• IMDC model retains prognostic value for ICI-treated patients, but performs best in first 6 months.

• For nivolumab/ipilimumab, objective response rates are approximately 40% regardless of IMDC score, highlighting limitations as a predictive biomarker.

• Sarcomatoid histology remains the only actionable predictive biomarker .

Take-home Message: IMDC score identifies patients at risk of early mortality (poor-risk) and patients at risk of overtreatment (favorable-risk), but predictive biomarkers are urgently needed to guide therapy selection .

Emerging Biomarkers: ctDNA and KIM-1

Journal/Author: UroToday (Khorasanchi A, Yang Y, 2023)

Circulating Tumor DNA (ctDNA):

• A tissue-informed ctDNA assay (Signatera™) in 45 patients with localized RCC showed that those with detectable ctDNA levels either before or after surgery had significantly worse recurrence-free survival than those with undetectable levels (HR 2.70; HR 3.23, respectively) .

Kidney Injury Molecule-1 (KIM-1):

• Higher KIM-1 levels post-nephrectomy are associated with a higher risk of recurrence.

• Patients with higher baseline KIM-1 levels were enriched for improved response to adjuvant atezolizumab compared to placebo in the IMmotion010 trial .

Take-home Message: These biomarkers need to be prospectively validated before becoming standard of care, but they hold promise for more accurately identifying patients at the highest risk of recurrence and overcoming limitations associated with contemporary risk models .

🔬 HIF-2α INHIBITION AND EMERGING THERAPIES

LITESPARK-012 (Belzutifan Combinations in First-Line RCC)

Journal/Author: JCO Oncology Practice (Grigg CM, et al., 2025)

Design: Ongoing phase 3 trial randomizing patients 1:1:1 to first-line pembrolizumab + lenvatinib with or without either belzutifan (HIF-2α inhibitor) or quavonlimab (anti-CTLA-4).

Population: Previously untreated advanced RCC.

Primary Outcome: Progression-free survival and overall survival.

Rationale: Belzutifan represents a novel class targeting the hypoxia-inducible factor pathway, already approved in von Hippel-Lindau-associated RCC.

Take-home Message: Results from LITESPARK-012 may provide definitive guidance on the incremental value of HIF-2α inhibition in first-line combination therapy.

📊 SUMMARY OF KEY THERAPEUTIC SHIFTS IN RCC

LANDMARK OVERACTIVE BLADDER (OAB) TRIALS

🔬 PHARMACOTHERAPY: BETA-3 ADRENERGIC RECEPTOR AGONISTS

Mirabegron Phase 3 Registration Trials and Systematic Review

Journal/Author: European Urology Focus (Dey A, et al., 2025); PubMed

Design: Comprehensive systematic review and meta-analysis of 28 randomized controlled trials (RCTs) evaluating mirabegron versus placebo and other active comparators in patients with OAB syndrome. The review was registered with PROSPERO (CRD42020200394) and followed PRISMA guidelines .

Population: 27,481 adults with OAB across 28 RCTs, comparing mirabegron at various doses (25 mg, 50 mg) against placebo, tolterodine, solifenacin, and oxybutynin .

Key Findings:

Conclusion: Mirabegron is effective, safe, and well tolerated for treating overactive bladder. When used in conjunction with anticholinergic medications, it provides additive benefits without causing more side effects .

Take-home Message: This comprehensive meta-analysis establishes mirabegron as a first-line pharmacotherapy option with favorable efficacy and tolerability compared to traditional anticholinergics, particularly with lower rates of dry mouth and other anticholinergic side effects .

EMPOWUR Trial (Vibegron Phase 3 Registration)

Journal/Author: Journal of Urology (Staskin D, et al., 2020); cited in

Design: Randomized, double-blind, placebo- and active-controlled phase 3 trial evaluating vibegron 75 mg daily versus placebo and tolterodine extended-release 4 mg.

Population: Adults with OAB symptoms, including urgency urinary incontinence (UUI).

Primary Outcome: Reduction in daily micturitions and UUI episodes at 12 weeks.

• Result: Vibegron 75 mg significantly improved OAB symptoms compared to placebo, with statistically significant improvements observed as early as week 2 and sustained through week 12 .

• Efficacy: Numerically better results compared to tolterodine, though the difference was not statistically significant .

Safety Outcomes:

• Vibegron was well-tolerated with adverse event rates (including hypertension) comparable to placebo .

• Unlike mirabegron, vibegron does not inhibit CYP2D6, a critical metabolic pathway for drugs commonly prescribed to older adults (donepezil, tramadol, venlafaxine) .

40-Week Extension:

• Sustained efficacy of vibegron was demonstrated, with statistical significance in favor of vibegron compared to tolterodine for incontinence .

• Adverse events: Vibegron and tolterodine had comparable rates of hypertension (8.8% vs. 8.6%) and UTI (6.6% vs. 7.3%).

• Vibegron had lower incidence of dry mouth (1.8% vs. 5.2%) but higher rates of constipation (3.7% vs. 2.6%) and headache (5.5% vs. 3.9%) .

Take-home Message: Vibegron is a selective β3-adrenoceptor agonist with comparable efficacy to mirabegron and a favorable safety profile, including no CYP2D6 inhibition—an important consideration for polypharmacy in older adults .

COURAGE Trial (Vibegron in Men with BPH and OAB)

Journal/Author: Journal of Urology (Staskin D, et al., 2024); Translational Andrology and Urology(Anis O, et al., 2025)

Design: Phase 3 multicenter, randomized, double-blind, placebo-controlled trial specifically evaluating vibegron 75 mg daily in men receiving pharmacologic treatment for benign prostatic hyperplasia (BPH).

Population: 965 men aged ≥45 years with OAB symptoms (>8 micturitions and >3 urgency episodes per day for >2 months) and BPH. All participants were on stable alpha-blocker therapy (initiated ≥3 months before screening), with or without 5α-reductase inhibitors (initiated ≥6 months before screening). Baseline IPSS ≥8 and minimum of two nocturia episodes .

Primary Outcomes: Daily micturition frequency and urgency episodes at 12 weeks.

• Result: Vibegron demonstrated statistically significant reductions compared to placebo in both co-primary endpoints .

• Improvements were reported as early as week 1, continued through week 8, and were generally maintained or improved through the 24-week study .

Key Secondary Outcomes at 12 Weeks:

• Significant reduction in nocturia and urgency urinary incontinence episodes

• Greater percentage of patients achieving ≥50% and ≥75% reduction in urgency episodes

• Significant improvements in IPSS storage scores and volume voided per micturition

Safety:

• Dropout rate due to adverse events: 3% (vibegron) vs. 2.7% (placebo)

• Treatment-emergent adverse event rates: 45.0% (vibegron) vs. 39.0% (placebo)

• Most common events: hypertension, COVID-19, UTI, hematuria

• No treatment-related serious adverse events reported

• Urinary retention rates: 0.9% (vibegron) vs. 0.5% (placebo)

• Hypertension incidence similar between groups despite most participants having pre-existing hypertension

Significance: This well-designed study specifically addresses storage symptoms in men receiving treatment for benign prostatic obstruction. The 2021 AUA guidelines recommend offering β3-adrenergic receptor agonists in combination with alpha-blockers for patients with moderate to severe predominant storage LUTS, and the COURAGE trial provides high-quality evidence supporting this recommendation .

Limitations:

• Excluded patients with maximum flow rate <5.0 mL/s or history of urinary retention

• Does not include men with BPO and OAB symptoms not receiving pharmacologic treatment

• Prostate volume and baseline PVR not included in inclusion criteria or reported results

• Only 23% of patients were on 5α-reductase inhibitors

• IPSS voiding score not reported, so potential negative impacts on voiding symptoms cannot be assessed

Take-home Message: Vibegron is effective and safe for treating OAB symptoms in men with BPH receiving alpha-blocker therapy, with rapid onset of action (week 1), sustained efficacy through 24 weeks, and a hypertension risk comparable to placebo .

🔬 COMPARATIVE EFFECTIVENESS: MIRABEGRON VS. VIBEGRON

Mirabegron vs. Vibegron Meta-Analysis (Female Patients)

Journal/Author: Urology (Liang P, et al., 2025); Epistemonikos

Design: Systematic review and meta-analysis of RCTs comparing mirabegron and vibegron in female patients with OAB, following PRISMA guidelines.

Population: 371 patients from 3 RCTs.

Key Findings:

• Urgency urinary incontinence: Vibegron was more effective than mirabegron (MD 0.25; 95% CI 0.04-0.47; p=0.02) .

• Similar efficacy for OAB symptom score, urgency, quality of life, and mean volume voided per micturition (all p>0.05).

• Safety outcomes: No significant differences in total adverse events, dry mouth, constipation, elevated PVR, or dizziness.

Conclusion: In female OAB patients, the efficacy and safety of mirabegron and vibegron were similar. Vibegron may be more effective than mirabegron in relieving urgency urinary incontinence .

Take-home Message: Both beta-3 agonists are effective options, with comparable safety profiles. The choice may be guided by specific patient characteristics, drug interactions (vibegron lacks CYP2D6 inhibition), and payer considerations.

🔬 THIRD-LINE THERAPIES: BOTULINUM TOXIN VS. SACRAL NEUROMODULATION

BoNT-A vs. SNM Systematic Review and Meta-Analysis

Journal/Author: Toxins (2025); NIH PMC

Design: Systematic review and meta-analysis following PRISMA guidelines, comparing intradetrusor onabotulinumtoxinA (BoNT-A) with placebo and sacral neuromodulation (SNM) for refractory OAB in women.

Population: Pooled data from 12 studies (9 RCTs, 3 cohort studies) with 2,645 patients with refractory OAB .

Key Findings: BoNT-A vs. Placebo (3-month follow-up):

• Complete resolution of UUI: 20.6% (BoNT-A) vs. 5.3% (placebo); OR 4.88 (95% CI 3.02-7.87; p<0.00001) .

• ≥75% reduction in UUI episodes: 39.5% vs. 13.7%; OR 4.40 (95% CI 2.64-7.33; p<0.00001) .

• UTI risk: Significantly higher with BoNT-A compared to placebo .

Key Findings: BoNT-A vs. SNM (6-month follow-up):

• UUI reduction: BoNT-A significantly reduced UUI episodes compared to SNM (p=0.0008) .

• ≥75% reduction in UUI: More likely with BoNT-A compared to SNM (p<0.00001) .

• Complete UUI resolution: SNM demonstrated a higher rate of complete resolution compared to BoNT-A (p<0.00001) .

• Quality of life: No significant difference between BoNT-A and SNM (p=0.2) .

• UTI risk: Higher with BoNT-A than SNM .

Study Heterogeneity: Consistency across outcomes was good, with I² <50% in 70.8% of analyses .

Conclusion: While BoNT-A offers robust symptom control, its safety profile necessitates careful patient selection. SNM remains a viable alternative for those prioritizing fewer adverse events. The study highlights the need for standardized outcome reporting, long-term cost-effectiveness analyses, and personalized treatment approaches .

Take-home Message: For refractory OAB, BoNT-A provides superior symptom reduction but carries higher UTI risk, while SNM offers better complete resolution rates and a more favorable adverse event profile. Patient preference, comorbidities, and willingness to accept adverse events should guide shared decision-making .

🔬 NEUROMODULATION: EMERGING TECHNOLOGIES

OASIS Trial (Revi System – Implantable Tibial Neuromodulation)

Journal/Author: Neurourology and Urodynamics (Heesakkers JPFA, et al., 2024); Urology Times

Design: Prospective, multicenter, single-arm, open-label pivotal trial evaluating the BlueWind Revi System, an implantable tibial neuromodulation device for OAB.

Population: 151 female patients with OAB implanted across US and European sites. Baseline: average 4.8 UUI episodes/day, 10 voids/day. Mean age 58.8 years .

Primary Efficacy Endpoint: Proportion of responders (≥50% improvement in average UUI episodes).

• 6-month follow-up: 76.4% response rate

• 12-month follow-up: 78.4% response rate

• Both reached statistical significance vs. predefined performance goal (p<0.0001) .

Key Secondary Outcomes:

• Among patients with completed 12-month diaries (n=139):

  • 82% achieved ≥50% reduction in UUI episodes

  • 66.9% achieved ≥75% reduction

  • 37.8% classified as dry at 6 months; 50% dry at 12 months

• 88% demonstrated significant improvement in either UUI episodes or severe UUI episodes

• Patient Global Impression of Improvement: 93.5% indicated improvement

• Treatment preference: 94.2% willing to continue; 98.5% preferred self-treatment sessions (up to 1 hour); 91.5% preferred up to 2 sessions/day

• Quality of life: 84.6% demonstrated average improvement exceeding the 10-point minimum clinically important difference

Safety:

• No procedure- or device-related serious adverse events

• No patients required surgical reintervention or revision due to implant migration, lead breakage, or battery replacement

• 15 serious AEs and 285 AEs reported

Take-home Message: The Revi System demonstrates excellent safety and efficacy for OAB, with high patient satisfaction and willingness to continue treatment. This implantable tibial neuromodulation device received FDA De Novo classification in August 2023 .

TITAN 2 Study (Implantable Tibial Neuromodulation Device)

Journal/Author: AUGS 2025 Meeting (presented by Linder BJ); Mayo Clinic

Design: Pivotal study evaluating an implantable tibial neuromodulation (iTNM) device—smaller than a quarter, implanted near the ankle via a minimally invasive outpatient procedure under local anesthesia.

Population: 188 adults with urgency incontinence underwent device placement.

Primary Endpoint: ≥50% reduction in urgency leakage episodes at 6 months.

• Result: 59% of patients achieved the primary endpoint .

12-Month Outcomes:

• Mean reduction of 2.7 leakage episodes per day

• Device-related adverse events predominantly mild to moderate

• One severe event (C. difficile infection) that fully resolved

Device Specifications: Rechargeable, with projected battery life of 10-15 years .

Take-home Message: The iTNM device offers a meaningful improvement in symptoms while substantially reducing treatment burden compared to traditional PTNS. It represents a compelling, less invasive alternative to sacral neuromodulation, especially for patients reluctant to undergo sacral procedures . The device received FDA approval in September 2025.

PEER 2 Study (Sacral Evoked Response Sensing)

Journal/Author: Urogynecology (2025); AUGS 2025 Meeting; Mayo Clinic

Design: Feasibility study investigating closed-loop sacral neuromodulation by integrating real-time physiological sensing. Traditional SNM programming depends on patient-reported sensory thresholds; this study evaluated objective sacral evoked responses (SERs) measured directly from the stimulation lead.

Population: 90 implant procedures with recorded SERs.

Key Findings:

• Strong correlation between lead-measured sacral evoked response thresholds (SERTs) and patient-reported sensory thresholds .

• In repeated testing, SERTs demonstrated far greater consistency than sensory thresholds:

  • 48% of repeat SERT measures were identical

  • Only 17% of repeat sensory thresholds were identical

Take-home Message: SER-based programming may provide a reliable, reproducible objective biomarker of sacral nerve activation, enabling more standardized programming across patients and potentially setting the stage for closed-loop SNM that adapts dynamically to the physiological state of the bladder .

PNE Implantation Technique Study (Fluoroscopic vs. Landmark-Guided)

Journal/Author: ICS 2025 (Anis O, et al.); Cleveland Clinic

Design: Retrospective cohort study comparing fluoroscopy-guided versus bony landmark-guided techniques for peripheral nerve evaluation (PNE) in sacral neuromodulation trials.

Population: 362 patients (mean age 64.6 years). Indications: UUI (239 patients), OAB dry (64 patients), non-obstructive urinary retention, fecal incontinence, and dual incontinence.

Primary Outcome: Symptom improvement leading to full SNM implant.

• Result: No significant difference in PNE success between fluoroscopic and landmark-guided techniques (p=0.81) .

• Consistent finding in OAB subgroups (UUI p=0.49; OAB dry p=0.08).

Predictors of Success: The only factor associated with success rates was the indication for PNE. Patients with NOUR (OR 0.16; p=0.001) and dual incontinence (OR 0.07; p=0.022) were less likely to proceed to full implant compared to those with UUI alone, regardless of technique.

Take-home Message: Fluoroscopy and landmark-guided PNE offer similar success rates. Clinicians may offer PNE based on their comfort with each technique and availability of equipment, without compromising patient outcomes .

🔬 ONGOING AND REGISTRATION TRIALS

Taiwan OAB Study (Medication vs. Botox)

Journal/Author: ICHGCP (Shen CT, Mackay Medical College); updated June 2025

Design: Clinical trial investigating different treatment options for OAB in Taiwanese patients, comparing oral medications (solifenacin, mirabegron) with Botox injections using advanced urodynamic measurements.

Primary Outcomes: Pressure-volume dynamics and compliance dynamics (how the bladder expands during filling). Measurements taken before treatment and at several points afterward.

Population: Female patients with OAB only, excluding those with diabetes or stroke history.

Significance: This research directly compares different treatment approaches using objective bladder function measurements, with follow-up up to one year. Results may help identify which patients respond best to which treatment .

Status: Recruiting.

📊 SUMMARY OF KEY THERAPEUTIC SHIFTS IN OAB